27HLA‑B27 typing

27 HLA‑B27 typing

If a pathology service mentioned in item 71148, 73320 or 73321 is rendered as a pathologist‑determinable service, the amount mentioned in the item is not payable for a pathology service mentioned in the item unless the recognised pathologist who renders the service records, in writing, the reasons for rendering the service and the result of the pathology service mentioned in item 71147.

Part 3 Services and fees

<table cellspacing="0" cellpadding="0" style="width:388.15pt; border-collapse:collapse"><thead><tr><td colspan="2" style="width:36.3pt; border-bottom:0.75pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableColHead"><span>Item</span></p></td><td style="width:285.5pt; border-bottom:0.75pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableColHead"><span>Pathology service</span></p></td><td colspan="4" style="width:34.25pt; border-bottom:0.75pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableColHead" style="text-align:right"><span>Fee</span><span> </span><span>($)</span></p></td></tr></thead><tbody><tr><td colspan="7" style="width:377.45pt; border-top:0.75pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableColHead"><span>Group P1</span><span> </span><span>— Haematology</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65060</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Haemoglobin, erythrocyte sedimentation rate, blood viscosity</span><span> </span><span>— 1 or more tests</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>7.90</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65066</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Examination of:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a blood film by special stains to demonstrate Heinz bodies, parasites or iron; or</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a blood film by enzyme cytochemistry for neutrophil alkaline phosphatase, alpha</span><span>‑</span><span>naphthyl acetate esterase or chloroacetate esterase; or</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a blood film using any other special staining methods including periodic acid Schiff and Sudan Black; or</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(d)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a urinary sediment for haemosiderin;</span></p><p class="paratable"><span>including a service described in item 65072</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>10.45</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65070</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p style="margin-top:6pt; font-size:11pt"><span>Erythrocyte count, haematocrit, haemoglobin, calculation or measurement of red cell index or indices, platelet count, leucocyte count and manual or instrument generated differential count (not being a service where haemoglobin only is requested)</span><span> </span><span>— 1 or more instrument</span><span>‑</span><span>generated set of results from a single sample and (if performed):</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a morphological assessment of a blood film; and</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>any service in item 65060 or 65072</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>17.05</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65072</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Examination for reticulocytes including a reticulocyte count by any method</span><span> </span><span>— 1 or more tests</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>10.25</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65075</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Haemolysis or metabolic enzymes</span><span> </span><span>— assessment by 1</span><span> </span><span>or more of the following tests:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>erythrocyte autohaemolysis test;</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>erythrocyte osmotic fragility test;</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>sugar water test;</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(d)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>G</span><span>‑</span><span>6</span><span>‑</span><span>P D (qualitative or quantitative) test;</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(e)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>pyruvate kinase (qualitative or quantitative) test;</span></p><p class="TableP1a"><span style="width:9.41pt; text-indent:0pt; display:inline-block"></span><span>(f)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>acid haemolysis test;</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>52.30</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span></span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(g)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>quantitation of muramidase in serum or urine;</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(h)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>Donath Landsteiner antibody test;</span></p><p class="TableP1a"><span style="width:10.02pt; text-indent:0pt; display:inline-block"></span><span>(i)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>other erythrocyte metabolic enzyme tests</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>90.80</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65078</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Tests for the diagnosis of thalassaemia consisting of haemoglobin electrophoresis or chromatography and at least 2</span><span> </span><span>of:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>examination for HbH; or</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>quantitation of HbA2; or</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>quantitation of HbF;</span></p><p class="TableText"><span>including (if performed) any service described in item</span><span> </span><span>65060 or 65070</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>90.80</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65079</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableP1a" style="margin-left:0pt; text-indent:0pt"><span>A test described in item 65078 if rendered by a receiving APP — 1 or more tests</span></p><p class="TableP1a"><span>(Item is subject to rules 18 and 18A)</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>90.80</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65081</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Tests for the investigation of haemoglobinopathy consisting of haemoglobin electrophoresis or chromatography and at least 1</span><span> </span><span>of:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>heat denaturation test; or</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>97.25</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span></span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>isopropanol precipitation test; or</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>tests for the presence of haemoglobin S; or</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(d)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>quantitation of any haemoglobin fraction (including S, C, D, E);</span></p><p class="TableText"><span>including (if performed) any service described in item</span><span> </span><span>65060, 65070 or 65078</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span></span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65082</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A test described in item 65081 if rendered by a receiving APP — 1 or more tests</span></p><p class="TableText"><span>(Item is subject to rules 18 and 18A)</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>97.25</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65084</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Bone marrow trephine biopsy</span><span> </span><span>— histopathological examination of sections of bone marrow and examination of aspirated material (including clot sections where necessary), including (if performed) any test described in item 65060, 65066 or 65070</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>166.95</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65087</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Bone marrow</span><span> </span><span>— examination of aspirated material (including clot sections where necessary), including (if performed) any test described in item 65060, 65066 or</span><span> </span><span>65070</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>83.65</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65090</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Blood grouping (including back</span><span>‑</span><span>grouping if performed)</span><span> </span><span>— ABO and Rh (D antigen)</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>11.20</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65093</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Blood grouping</span><span> </span><span>— Rh phenotypes, Kell system, Duffy system, M and N factors or any other blood group system</span><span> </span><span>— 1 or more systems, including item 65090 (if performed)</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>22.15</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65096</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Blood grouping (including back</span><span>‑</span><span>grouping if performed), and examination of serum for Rh and other blood group antibodies, including:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>identification and quantitation of any antibodies detected; and</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>(if performed) any test described in item</span><span> </span><span>65060 or</span><span> </span><span>65070</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>41.30</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65099</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Compatibility tests by crossmatch</span><span> </span><span>— all tests performed on any 1 day for up to 6 units, including:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>all grouping checks of the patient and donor; and</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>examination for antibodies and, if necessary, identification of any antibodies detected; and</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>(if performed) any tests described in item</span><span> </span><span>65060, 65070, 65090 or 65096</span></p><p class="TableText"><span>(Item is subject to rule</span><span> </span><span>5)</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>109.65</span></p></td></tr><tr style="height:71pt"><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65102</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Compatibility tests by crossmatch</span><span> </span><span>— all tests performed on any 1 day in excess of 6 units, including:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>all grouping checks of the patient and donor; and</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>examination for antibodies and, if necessary, identification of any antibodies detected; and</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>165.70</span></p></td></tr><tr style="height:46pt"><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span></span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>(if performed) any tests described in item</span><span> </span><span>65060, 65070, 65090, 65096, 65099 or 65105</span></p><p class="TableText"><span>(Item is subject to rule 5)</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span></span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65105</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Compatibility testing using at least a 3 cell panel and issue of red cells for transfusion</span><span> </span><span>— all tests performed on any 1 day for up to 6 units, including:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>all grouping checks of the patient and donor; and</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>examination for antibodies and, if necessary, identification of any antibodies detected; and</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>109.65</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span></span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>(if performed) any tests described in item</span><span> </span><span>65060, 65070, 65090 or 65096</span></p><p class="TableText"><span>(Item is subject to rule 5)</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span></span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65108</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Compatibility testing using at least a 3 cell panel and issue of red cells for transfusion</span><span> </span><span>— all tests performed on any 1 day in excess of 6 units, including:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>all grouping checks of the patient and donor; and</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>examination for antibodies and, if necessary, identification of any antibodies detected; and</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>(if performed) any tests described in item</span><span> </span><span>65060, 65070, 65090, 65096, 65099 or 65105</span></p><p class="TableText"><span>(Item is subject to rule 5)</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>165.70</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65109</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableP1a" style="margin-left:0pt; text-indent:0pt"><span>Release of fresh frozen plasma or cryoprecipitate for the use in a patient for the correction of a coagulopathy — 1 release</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>13.00</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65110</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableP1a" style="margin-left:0pt; text-indent:0pt"><span>Release of compatible fresh platelets for the use in a patient for platelet support as prophylaxis to minimize bleeding or during active bleeding — 1 release</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>13.00</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65111</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Examination of serum for blood group antibodies (including identification and, if necessary, quantitation of any antibodies detected)</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>23.35</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65114</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>1 or more of the following tests:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>direct Coombs (antiglobulin) test;</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>qualitative or quantitative test for cold agglutinins or heterophil antibodies</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>9.15</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65117</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>1 or more of the following tests:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>spectroscopic examination of blood for chemically altered haemoglobins;</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>detection of methaemalbumin (Schumm’s test)</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>20.40</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65120</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Prothrombin time (including INR where appropriate), activated partial thromboplastin time, thrombin time (including test for the presence of heparin), test for factor XIII deficiency (qualitative), Echis test, Stypven test, reptilase time, fibrinogen, or 1 of fibrinogen degradation products, fibrin monomer or D</span><span>‑</span><span>dimer</span><span> </span><span>— 1</span><span> </span><span>test</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>13.80</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="page-break-inside:avoid; page-break-after:avoid"><span>65123</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="page-break-inside:avoid; page-break-after:avoid"><span>2 tests described in item 65120</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right; page-break-inside:avoid; page-break-after:avoid"><span>20.50</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65126</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>3 tests described in item 65120</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>28.05</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65129</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>4 or more tests described in item 65120</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>35.75</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65137</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A test for the presence of lupus anticoagulant, not being a service connected with a service to which item 65175, 65176, 65177, 65178 or 65179 applies</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>25.50</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65142</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Confirmation or clarification of an abnormal or indeterminate result of a test mentioned in item</span><span> </span><span>65175, by testing a specimen collected on a different day</span><span> </span><span>— 1</span><span> </span><span>or more tests</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>25.50</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65144</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Platelet aggregation in response to ADP, collagen, 5HT, ristocetin or other substances; or heparin, low molecular weight heparins, heparinoid or other drugs</span><span> </span><span>— 1 or more tests</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>56.95</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65147</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of anti</span><span>‑</span><span>Xa activity when monitoring is required for a patient receiving a low molecular weight heparin or heparinoid</span><span> </span><span>— 1 test</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>38.15</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65150</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of von Willebrand factor antigen, von Willebrand factor activity (ristocetin cofactor assay), von Willebrand factor collagen binding activity, factor</span><span> </span><span>II, factor V, factor VII, factor VIII, factor IX, factor X, factor XI, factor XII, factor</span><span> </span><span>XIII, Fletcher factor, Fitzgerald factor, circulating coagulation factor inhibitors other than by Bethesda assay</span><span> </span><span>— 1 test</span></p><p class="TableText"><span>(Item is subject to rule 6)</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>71.40</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65153</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>2 tests described in item 65150</span></p><p class="TableText"><span>(Item is subject to rule 6)</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>142.80</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65156</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>3 or more tests described in item 65150</span></p><p class="TableText"><span>(Item is subject to rule 6)</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>214.20</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65157</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A test described in item 65150, if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP — 1 test</span></p><p class="TableText"><span>(Item is subject to rules 6, 18 and 18A)</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>71.40</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65158</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A test described in item 65150, if rendered by a receiving APP, where 1 or more tests in the item have been rendered by the referring APP</span><span> </span><span>— 1 test</span></p><p class="TableText"><span>(Item is subject to rules 6, 18 and 18A)</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>71.40</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65159</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of circulating coagulation factor inhibitors by Bethesda assay</span><span> </span><span>— 1 test</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>71.40</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65162</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Examination of a maternal blood film for the presence of fetal red blood cells (Kleihauer test)</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>10.50</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65165</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Detection and quantitation of fetal red blood cells in the maternal circulation by detection of red cell antigens using flow cytometric methods including (if performed) any test described in item</span><span> </span><span>65070 or 65162</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>34.70</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65166</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A test described in item 65165 if rendered by a receiving APP</span><span> </span><span>— 1 or more tests</span></p><p class="TableText"><span>(Item is subject to rules 18 and 18A)</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>34.70</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65171</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A test for the presence of antithrombin III deficiency, protein C deficiency, protein S deficiency or activated protein C resistance in a first degree relative of a person who has a proven deficiency mentioned in this item</span><span> </span><span>— 1 or more tests</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>25.50</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65175</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A test for the presence of antithrombin</span><span> </span><span>III deficiency, protein C deficiency, protein S deficiency, lupus anticoagulant, activated protein C resistance, if the request for the test specifically identifies that the patient has a history of venous thromboembolism</span><span> </span><span>— quantitation by 1 or more techniques</span><span> </span><span>— 1</span><span> </span><span>test</span></p><p class="TableText"><span>(Item is subject to rule 6)</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>25.50</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65176</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>2 tests described in item</span><span> </span><span>65175</span></p><p class="TableText"><span>(Item is subject to rule 6)</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>49.00</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65177</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>3 tests described in item</span><span> </span><span>65175</span></p><p class="TableText"><span>(Item is subject to rule 6)</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>72.45</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65178</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>4 tests described in item</span><span> </span><span>65175</span></p><p class="TableText"><span>(Item is subject to rule 6)</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>95.85</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65179</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>5 tests described in item</span><span> </span><span>65175</span></p><p class="TableText"><span>(Item is subject to rule 6)</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>119.30</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65180</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A test described in item 65175, if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP — 1 test</span></p><p class="TableText"><span>(Item is subject to rules 6, 18 and 18A)</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>25.50</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65181</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A test described in item 65175, if rendered by a receiving APP, where 1 or more tests in the item have been rendered by the referring APP</span><span> </span><span>— 1 test</span></p><p class="TableText"><span>(Item is subject to rules 6, 18 and 18A)</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>23.45</span></p></td></tr><tr><td colspan="7" style="width:377.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableColHead"><span>Group P2</span><span> </span><span>— Chemical</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66500</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation in serum, plasma, urine or other body fluid (except amniotic fluid), by any method, except reagent tablet or reagent strip, (with or without reflectance meter) of acid phosphatase, alanine aminotransferase, albumin, alkaline phosphatase, ammonia, amylase, aspartate aminotransferase, bicarbonate, bilirubin (total), bilirubin (any fractions), C</span><span>‑</span><span>reactive protein, calcium (total or corrected for albumin), chloride, creatine kinase, creatinine, gamma glutamyl transferase, globulin, glucose, lactate dehydrogenase, lipase, magnesium, phosphate, potassium, sodium, total cholesterol, total protein, triglycerides, urate or urea</span><span> </span><span>— 1 test</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>9.75</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66503</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>2 tests described in item 66500</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>11.75</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66506</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>3 tests described in item 66500</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>13.75</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66509</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>4 tests described in item 66500</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>15.75</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66512</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>5 or more tests described in item 66500</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>17.80</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66517</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of bile acids in blood in pregnancy</span></p><p class="TableText"><span>(Item is subject to rule 25)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>19.80</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66518</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Investigation of cardiac or skeletal muscle damage by quantitative measurement of creatine kinase isoenzymes, troponin or myoglobin in blood</span><span> </span><span>— tests performed on only 1</span><span> </span><span>specimen in a 24 hour period</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>20.20</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66519</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Investigation of cardiac or skeletal muscle damage by quantitative measurement of creatine kinase isoenzymes, troponin or myoglobin in blood</span><span> </span><span>— tests performed on 2 or more specimens in a 24 hour period</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>40.40</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66536</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of HDL cholesterol</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>11.10</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66539</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Electrophoresis of serum for demonstration of lipoprotein subclasses:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>if the cholesterol is &gt;6.5</span><span> </span><span>mmol/L and triglyceride &gt;4.0 mmol/L; or</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>in the diagnosis of types III and IV hyperlipidaemia</span></p><p class="TableText"><span>(Item is subject to rule 25)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>30.80</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66542</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Oral glucose tolerance test for the diagnosis of diabetes mellitus, that includes:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>administration of glucose; and</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>at least 2 measurements of blood glucose; and</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>(if performed) any test described in item</span><span> </span><span>66695</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>19.10</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66545</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Oral glucose challenge test in pregnancy for the detection of gestational diabetes that includes:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>administration of glucose; and</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>1 or 2 measurements of blood glucose; and</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>(if performed) any test in item 66695</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>15.90</span></p></td></tr><tr style="height:44pt"><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66548</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Oral glucose tolerance test in pregnancy for the diagnosis of gestational diabetes that includes:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>administration of glucose; and</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>20.05</span></p></td></tr><tr style="height:31pt"><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span></span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>at least 3 measurements of blood glucose; and</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>(if performed) any test in item 66695</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span></span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66551</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of glycosylated haemoglobin performed in the management of established diabetes</span><span></span></p><p class="TableText"><span>(Item is subject to rule 25)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>16.90</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66554</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of glycosylated haemoglobin performed in the management of pre</span><span>‑</span><span>existing diabetes where the patient is pregnant</span><span> </span><span>— including a service in item 66551 (if performed)</span></p><p class="TableText"><span>(Item is subject to rule 25)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>16.90</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66557</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of fructosamine performed in the management of established diabetes</span><span> </span><span>— each test to a maximum of 4 tests in a 12</span><span> </span><span>month period</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>9.75</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66560</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Microalbumin</span><span> </span><span>— quantitation in urine</span><span></span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>20.25</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66563</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Osmolality, estimation by osmometer, in serum or in urine</span><span> </span><span>— 1</span><span> </span><span>or more tests</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>24.85</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66566</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>blood gases (including pO</span><span style="font-size:8pt; vertical-align:-2pt">2</span><span>, oxygen saturation and pCO</span><span style="font-size:8pt; vertical-align:-2pt">2</span><span>); and</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>33.95</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span></span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>bicarbonate and pH;</span></p><p class="TableText"><span>including any other measurement (eg haemoglobin, lactate, potassium or ionised calcium) or calculation performed on the same specimen</span><span> </span><span>— 1</span><span> </span><span>or more tests on 1</span><span> </span><span>specimen</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span></span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66569</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of blood gases, bicarbonate and pH as described in item 66566 on 2 specimens performed on any 1 day</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>42.90</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66572</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of blood gases, bicarbonate and pH as described in item 66566 on 3 specimens performed on any 1 day</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>51.90</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66575</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of blood gases, bicarbonate and pH as described in item 66566 on 4 specimens performed on any 1 day</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>60.85</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66578</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of blood gases, bicarbonate and pH as described in item 66566 on 5 specimens performed on any 1 day</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>69.80</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66581</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of blood gases, bicarbonate and pH as described in item 66566 on 6 or more specimens performed on any 1 day</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>78.80</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66584</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of ionised calcium (except if performed as part of item 66566)</span><span> </span><span>— 1 test</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>9.75</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66587</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Urine acidification test for the diagnosis of renal tubular acidosis including the administration of an acid load, and pH measurements on 4 or more urine specimens and at least 1 blood specimen</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>47.85</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66590</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Calculus, analysis of 1 or more</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>30.80</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66593</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Ferritin</span><span> </span><span>— quantitation, except if requested as part of iron studies</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>18.10</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66596</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Iron studies, consisting of quantitation of:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>serum iron; and</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>transferrin or iron binding capacity; and</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>ferritin</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>32.75</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66599</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Serum B12 or red cell folate and, if required, serum folate</span></p><p class="TableText"><span>(Item is subject to rule 21)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>23.75</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66602</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Serum B12 and red cell folate and, if required, serum folate</span></p><p class="TableText"><span>(Item is subject to rule 21)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>43.25</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66605</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Vitamins</span><span> </span><span>— quantitation of vitamins B1, B2, B3, B6 and C in blood, urine or other body fluid</span></p><p class="TableText"><span>(Item is subject to rule 25)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>30.80</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66606</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A test described in item 66605 if rendered by a receiving APP — 1 or more tests</span></p><p class="TableText"><span>(Item is subject to rules 18, 18A and 25)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>30.80</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66607</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Vitamins</span><span> </span><span>— quantitation of vitamins A and E in blood, urine or other body fluid</span></p><p class="TableText"><span>(Item is subject to rule 25)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>76.27</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66608</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Vitamin D or D fractions</span><span> </span><span>— 1 or more tests</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>42.55</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66609</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A test described in item 66608 if rendered by a receiving APP — 1 or more tests</span></p><p class="TableText"><span>(Item is subject to rules 18 and 18A)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>42.55</span></p></td></tr><tr style="height:85.5pt"><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66623</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>All qualitative and quantitative tests on blood, urine or other body fluid for:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a drug or drugs of abuse (including illegal drugs and legally available drugs taken other than in appropriate dosage); or</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>ingested or absorbed toxic chemicals;</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>41.80</span></p></td></tr><tr style="height:81.75pt"><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span></span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>including a service described in item 66800, 66803, 66806, 66812 or 66815 (if performed), but excluding:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the surveillance of sports people and athletes for performance improving substances; and</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(d)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the monitoring of patients participating in a drug abuse treatment program</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span></span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66626</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Detection or quantitation or both of a drug, or drugs, of abuse or a therapeutic drug, on a sample collected from a patient participating in a drug abuse treatment program, including all tests on blood, urine or other body fluid, not including:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the surveillance of sports people and athletes for performance improving substances; and</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the detection of nicotine and metabolites in smoking withdrawal programs</span></p><p class="TableText"><span>(Item is subject to rule 25)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>24.25</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66629</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Beta</span><span>‑</span><span>2</span><span>‑</span><span>microglobulin</span><span> </span><span>— quantitation in serum, urine or other body fluids</span><span> </span><span>— 1 or more tests</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>20.25</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66632</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Caeruloplasmin, haptoglobins, or prealbumin</span><span> </span><span>— quantitation in serum, urine or other body fluids</span><span> </span><span>— 1</span><span> </span><span>or more tests</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>20.25</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66635</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Alpha</span><span>‑</span><span>1</span><span>‑</span><span>antitrypsin</span><span> </span><span>— quantitation in serum, urine or other body fluid</span><span> </span><span>— 1 or more tests</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>20.25</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66638</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Isoelectric focussing or similar methods for determination of alpha</span><span>‑</span><span>1</span><span>‑</span><span>antitrypsin phenotype in serum</span><span> </span><span>— 1 or more tests</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>49.40</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66639</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A test described in item 66638 if rendered by a receiving APP — 1 or more tests</span></p><p class="TableText"><span>(Item is subject to rules 18 and 18A)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>29.40</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66641</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Electrophoresis of serum or other body fluid to demonstrate:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the isoenzymes of lactate dehydrogenase; or</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the isoenzymes of alkaline phosphatase;</span></p><p class="TableText"><span>including the preliminary quantitation of total relevant enzyme activity</span><span> </span><span>— 1 or more tests</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>29.40</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66642</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A test described in item 66641 if rendered by a receiving APP — 1 or more tests</span></p><p class="TableText"><span>(Item is subject to rules 18 and 18A)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>29.40</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66644</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>C</span><span>‑</span><span>1 esterase inhibitor</span><span> </span><span>— quantitation</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>20.30</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66647</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>C</span><span>‑</span><span>1 esterase inhibitor</span><span> </span><span>— functional assay</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>45.40</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66650</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Alpha</span><span>‑</span><span>fetoprotein, CA</span><span>‑</span><span>15.3 antigen (CA15.3), CA</span><span>‑</span><span>19.9 antigen (CA19.9), CA</span><span>‑</span><span>125 antigen (C125), cancer associated serum antigen (CASA), carcinoembryonic antigen (CEA), human chorionic gonadotrophin (HCG), neuron specific enolase (NSE) thyroglobulin in serum or other body fluid, in the monitoring of malignancy</span><span> </span><span>or in the detection or monitoring of gestational trophoblastic disease or a hepatic or germ cell tumour</span><span> </span><span>— quantitation</span><span> </span><span>— 1 test</span></p><p class="TableText"><span>(Item is subject to rule 6)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>24.50</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66651</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A test described in item 66650, if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP — 1 test</span></p><p class="TableText"><span>(Item is subject to rules 6, 18 and 18A)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>24.50</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66652</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A test described in item 66650, if rendered by a receiving APP, where 1 or more tests in the item have been rendered by the referring APP — 1 test</span></p><p class="TableText"><span>(Item is subject to rules 6, 18 and 18A)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>20.45</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66653</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>2 or more tests described in item 66650</span></p><p class="TableText"><span>(Item is subject to rule 6)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>44.90</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66655</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Prostate specific antigen — quantitation</span></p><p class="TableText"><span>(Item is subject to rule 25)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>20.30</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66656</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Prostate specific antigen (PSA) quantitation in the monitoring of previously diagnosed prostatic disease (including a test to which item</span><span> </span><span>66655 applies)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>20.30</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66659</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Prostate specific antigen (PSA), quantitation of 2</span><span> </span><span>or more fractions of PSA and any derived index, including, if performed, a test described in item 66656, in the follow up of a PSA result that lies at or above the age-related median but below the age-related, method-specific 97.5% reference limit</span></p><p class="TableText"><span>(Item is subject to rule 25)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>37.40</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66660</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Prostate specific antigen (PSA), quantitation of 2</span><span> </span><span>or more fractions of PSA and any derived index, including, if performed, a test described in item 66656, in the follow up of a PSA result that lies at or above the age</span><span>‑</span><span>related, method-specific 97.5% reference limit, but below 10 µg/L</span></p><p class="TableText"><span>(Item is subject to rule 25)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>37.80</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66662</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of hormone receptors on proven primary breast or ovarian carcinoma or a metastasis from a breast or ovarian carcinoma or a subsequent lesion in the breast</span><span> </span><span>— 1 or more tests</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>80.50</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66663</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A test described in item 66662 if rendered by a receiving APP — 1 or more tests</span></p><p class="TableText"><span>(Item is subject to rules 18 and 18A)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>80.50</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66665</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Lead quantitation in blood or urine (other than for occupational health screening purposes) to a maximum of 3 tests in a 6 month period</span><span> </span><span>— each test</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>30.80</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66666</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A test described in item 66665 if rendered by a receiving APP — 1 or more tests</span></p><p class="TableText"><span>(Item is subject to rules 18 and 18A)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>30.80</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66667</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of serum zinc in a patient receiving intravenous alimentation</span><span> </span><span>— each test</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>30.80</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66671</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of serum aluminium in a patient in a renal dialysis program</span><span> </span><span>— each test</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>37.15</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66674</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>faecal fat; or</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>breath hydrogen in response to loading with disaccharides;</span></p><p class="TableText"><span>1 or more tests within a 28 day period</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>40.20</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66677</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Test for tryptic activity in faeces in the investigation of diarrhoea of longer than 4 weeks duration in children under 6 years old</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>11.25</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66680</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of disaccharidases and other enzymes in intestinal tissue</span><span> </span><span>— 1 or more tests</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>74.95</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66683</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Enzymes</span><span> </span><span>— quantitation in solid tissue or tissues other than blood elements or intestinal tissue</span><span> </span><span>— 1</span><span> </span><span>or more tests</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>74.95</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66686</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Performance of 1 or more of the following procedures:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>growth hormone suppression by glucose loading;</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>growth hormone stimulation by exercise;</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>dexamethasone suppression test;</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(d)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>sweat collection by iontophoresis for chloride analysis;</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(e)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>pharmacological stimulation of growth hormone</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>51.00</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66695</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation in blood or urine of hormones and hormone binding proteins</span><span> </span><span>— ACTH, aldosterone, androstenedione, C</span><span>‑</span><span>peptide, calcitonin, cortisol, DHEAS, 11</span><span>‑</span><span>deoxycortisol, dihydrotestosterone, FSH, gastrin, glucagon, growth hormone, hydroxyprogesterone, insulin, LH, oestradiol, oestrone, progesterone, prolactin, PTH, renin, sex hormone binding globulin, somatomedin C(IGF</span><span> </span><span>–1), free or total testosterone, urine steroid fraction or fractions, vasoactive intestinal peptide</span><span> </span><span>— 1 test</span></p><p class="TableText"><span>(Item is subject to rule 6)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>30.70</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66696</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A test described in item 66695, if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP</span></p><p class="TableText"><span>(Item is subject to rules 6, 18 and 18A)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>30.70</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66697</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A test described in item 66695, if rendered by a receiving APP, where 1 or more tests in the item have been rendered by the referring APP</span><span> </span><span>— each test to a maximum of 4 tests</span></p><p class="TableText"><span>(Item is subject to rules 6, 18 and 18A)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>13.30</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66698</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>2 tests described in item 66695</span></p><p class="TableText"><span>(Item is subject to rule 6)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>44.00</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66701</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>3 tests described in item 66695</span></p><p class="TableText"><span>(Item is subject to rule 6)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>57.30</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66704</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>4 tests described in item 66695</span></p><p class="TableText"><span>(Item is subject to rule 6)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>70.60</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66707</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>5 or more tests described in item 66695</span></p><p class="TableText"><span>(Item is subject to rule 6)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>83.90</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66711</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation in saliva of cortisol in:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the investigation of Cushing’s syndrome; or</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the management of children with congenital adrenal hyperplasia;</span></p><p class="TableP1a"><span>1 test</span></p><p class="Query"><span style="font-weight:normal; font-style:normal">(Item is subject to rule 6)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>30.35</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66712</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>2 tests described in item 66711</span></p><p class="TableText"><span>(Item is subject to rule 6)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>43.35</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66714</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A test described in item 66711, if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP</span></p><p class="TableText"><span>(Item is subject to rules 6, 18 and 18A)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>30.35</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66715</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A test described in item 66711, if rendered by a receiving APP, where 1 test in the item has been rendered by the referring APP</span><span> </span><span>— 1 test</span></p><p class="TableText"><span>(Item is subject to rules 6, 18 and 18A)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>12.95</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66716</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>TSH quantitation</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>25.20</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66719</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Thyroid function tests (comprising the service described in item 66716 and 1 or more of the following tests</span><span> </span><span>— free thyroxine, free T3, for a patient, if at least 1 of the following conditions is satisfied:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the patient has an abnormal level of TSH;</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>35.05</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span></span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the tests are performed:</span></p><p class="TableP2i"><span style="width:25.92pt; text-indent:0pt; display:inline-block"></span><span>(i)</span><span style="width:7.1pt; text-indent:0pt; display:inline-block"> </span><span>for the purpose of monitoring thyroid disease in the patient; or</span></p><p class="TableP2i"><span style="width:22.86pt; text-indent:0pt; display:inline-block"></span><span>(ii)</span><span style="width:7.1pt; text-indent:0pt; display:inline-block"> </span><span>to investigate the sick euthyroid syndrome if the patient is an admitted patient; or</span></p><p class="TableP2i"><span style="width:19.81pt; text-indent:0pt; display:inline-block"></span><span>(iii)</span><span style="width:7.1pt; text-indent:0pt; display:inline-block"> </span><span>to investigate dementia or psychiatric illness of the patient; or</span></p><p class="TableP2i"><span style="width:20.42pt; text-indent:0pt; display:inline-block"></span><span>(iv)</span><span style="width:7.1pt; text-indent:0pt; display:inline-block"> </span><span>to investigate amenorrhoea or infertility of the patient;</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span></span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span></span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the medical practitioner who requested the tests suspects the patient has a pituitary dysfunction;</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(d)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the patient is on drugs that interfere with thyroid hormone metabolism or function</span></p><p class="TableText"><span>(Item is subject to rule 9)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span></span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66722</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>TSH quantitation described in item 66716 and 1</span><span> </span><span>test described in item 66695</span></p><p class="TableText"><span>(Item is subject to rule 6)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>38.15</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66723</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A test described in item 66722, if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP — 1 test</span></p><p class="TableText"><span>(Item is subject to rules 6, 18 and 18A)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>38.15</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66724</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A test described in item 66722, if rendered by a receiving APP, where 1 or more tests in the item have been rendered by the referring APP — 1 test</span></p><p class="TableText"><span>(Item is subject to rules 6, 18 and 18A)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>13.25</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66725</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>TSH quantitation described in item 66716 and 2</span><span> </span><span>tests described in item 66695</span></p><p class="TableText"><span>(Item is subject to rule 6)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>51.40</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66728</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>TSH quantitation described in item 66716 and 3</span><span> </span><span>tests described in item 66695</span></p><p class="TableText"><span>(Item is subject to rule 6)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>64.65</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66731</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>TSH quantitation described in item 66716 and 4</span><span> </span><span>tests described in item 66695</span></p><p class="TableText"><span>(Item is subject to rule 6)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>77.90</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66734</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>TSH quantitation described in item 66716 and 5</span><span> </span><span>tests described in item 66695</span></p><p class="TableText"><span>(Item is subject to rule 6)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>91.15</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66743</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of alpha</span><span>‑</span><span>fetoprotein in serum or other body fluids during pregnancy except if requested as part of item 66750 or 66751</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>20.25</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66749</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Amniotic fluid, spectrophotometric examination of, and quantitation of:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>lecithin/sphingomyelin ratio; or</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>palmitic acid, phosphatidylglycerol or lamellar body phospholipid; or</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>33.15</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span></span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>bilirubin, including correction for haemoglobin;</span></p><p class="TableText"><span>1 or more tests</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span></span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66750</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation, in pregnancy, of any 2 of the following to detect foetal abnormality:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>total human chorionic gonadotrophin (total HCG);</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>free alpha human chorionic gonadotrophin (free alpha HCG);</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>40.00</span></p></td></tr><tr style="height:57.75pt"><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span></span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>free beta human chorionic gonadotrophin (free beta HCG);</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(d)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>pregnancy associated plasma protein A (PAPP</span><span>‑</span><span>A);</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span></span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span></span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(e)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>unconjugated oestriol (uE</span><span style="font-size:7.33pt; vertical-align:sub">3</span><span>);</span></p><p class="TableP1a"><span style="width:9.41pt; text-indent:0pt; display:inline-block"></span><span>(f)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>alpha</span><span>‑</span><span>fetoprotein (AFP);</span></p><p class="TableText"><span>including (if performed) a service described in item</span><span> </span><span>73527 or 73529</span></p><p class="TableText"><span>(Item is subject to rule 25)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span></span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66751</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation, in pregnancy, of any 3 or more tests described in item 66750</span></p><p class="TableText"><span>(Item is subject to rule 25)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>55.60</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66752</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of acetoacetate, beta</span><span>‑</span><span>hydroxybutyrate, citrate, oxalate, total free fatty acids, cysteine, homocysteine, cystine, lactate, pyruvate or other amino acids and hydroxyproline (except if performed as part of item</span><span> </span><span>66773 or 66776)</span><span> </span><span>— 1</span><span> </span><span>test</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>24.85</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66755</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>2 or more tests described in item 66752</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>39.10</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66756</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p style="font-size:11pt"><span>Quantitation of 10 or more amino acids for the diagnosis of inborn errors of metabolism — up to 4</span><span> </span><span>tests in a 12 month period on specimens of plasma, CSF and urine</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>98.95</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66757</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p style="font-size:11pt"><span>Quantitation of 10 or more amino acids for monitoring of previously diagnosed inborn errors of metabolism in 1 tissue type</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>98.95</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66758</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of angiotensin converting enzyme, or cholinesterase</span><span> </span><span>— 1 or more tests</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>24.85</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66761</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Test for reducing substances in faeces by any method (except reagent strip or dipstick)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>13.25</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66764</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Examination for faecal occult blood (including tests for haemoglobin and its derivatives in the faeces except by reagent strip or dip stick methods) with a maximum of 3 examinations on specimens collected on separate days in a 28 day period</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>8.95</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66767</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>2 examinations described in item</span><span> </span><span>66764 performed on separately collected and identified specimens</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>17.95</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66770</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>3 examinations described in item</span><span> </span><span>66764 performed on separately collected and identified specimens</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>26.90</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66773</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of products of collagen breakdown or</span><span style="background-color:#e0e0e0"> </span><span>formation for the monitoring of patients with proven low bone mineral density and, if performed, a service described in item</span><span> </span><span>66752</span><span> </span><span>— 1 or more tests</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>24.80</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66776</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of products of collagen breakdown or</span><span style="background-color:#e0e0e0"> </span><span>formation for the monitoring of patients with metabolic bone disease or Paget’s disease of bone and, if performed, a service described in item 66752</span><span> </span><span>— 1</span><span> </span><span>or more tests</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>24.80</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66779</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Adrenaline, noradrenaline, dopamine, histamine, hydroxyindoleacetic acid (5HIAA), hydroxymethoxymandelic acid (HMMA), homovanillic acid (HVA), metanephrines, methoxyhydroxyphenylethylene glycol (MHPG), phenylacetic acid (PAA) or serotonin</span><span> </span><span>— quantitation</span><span> </span><span>— 1 or more tests</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>40.20</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66780</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A test described in item 66779 if rendered by a receiving APP — 1 or more tests</span></p><p class="TableText"><span>(Item is subject to rules 18 and 18A)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>40.20</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66782</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Porphyrins or porphyrins precursors</span><span> </span><span>— detection in plasma, red cells, urine or faeces</span><span> </span><span>— 1 or more tests</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>13.25</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66783</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A test described in item 66782 if rendered by a receiving APP — 1 or more tests</span></p><p class="TableText"><span>(Item is subject to rules 18 and 18A)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>13.25</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66785</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Porphyrins or porphyrins precursors</span><span> </span><span>— quantitation in plasma, red cells, urine or faeces</span><span> </span><span>— 1 test</span></p><p class="TableText"><span>(Item is subject to rule 6)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>40.20</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66788</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Porphyrins or porphyrins precursors</span><span> </span><span>— quantitation in plasma, red cells, urine or faeces</span><span> </span><span>— 2 or more tests</span></p><p class="TableText"><span>(Item is subject to rule 6)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>66.30</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66789</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A test described in item 66785 if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP — 1 test</span></p><p class="TableText"><span>(Item is subject to rules 6, 18 and 18A)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>40.20</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66790</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A test described in item 66785, if rendered by a receiving APP, where 1 or more tests in the item have been rendered by the referring APP — 1 test</span></p><p class="TableText"><span>(Item is subject to rules 6, 18 and 18A)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>26.05</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66791</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Porphyrin biosynthetic enzymes</span><span> </span><span>— measurement of activity in blood cells or other tissues</span><span> </span><span>— 1 or more tests</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>74.95</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66792</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A test described in item 66791 if rendered by a receiving APP — 1 or more tests</span></p><p class="TableText"><span>(Item is subject to rules 18 and 18A)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>74.95</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66800</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation in blood, urine or other body fluid by any method (except reagent tablet or reagent strip) of any of the following used therapeutically by the patient from whom the specimen was taken: amikacin, carbamazepine, digoxin, disopyramide, ethanol, ethosuximide, gentamicin, lignocaine, lithium, netilmicin, paracetamol, phenobarbitone, phenytoin, primidone, procainamide, quinidine, salicylate, theophylline, tobramycin, valproate or vancomycin</span><span> </span><span>— 1</span><span> </span><span>test</span></p><p class="TableText"><span>(Item is subject to rule 6)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>18.25</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66803</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>2 tests described in item 66800</span></p><p class="TableText"><span>(Item is subject to rule 6)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>30.70</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66804</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A test described in item 66800 if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP — 1 test</span></p><p class="TableText"><span>(Item is subject to rules 6, 18 and 18A)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>18.25</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66805</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A test described in item 66800, if rendered by a receiving APP, where 1 or more tests in the item have been rendered by the referring APP</span><span> </span><span>— 1 test</span></p><p class="TableText"><span>(Item is subject to rules 6, 18 and 18A)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>12.45</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66806</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>3 tests described in item 66800</span></p><p class="TableText"><span>(Item is subject to rule 6)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>42.15</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66812</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation, not elsewhere described in this table by any method or methods, in blood, urine or other body fluid, of a drug being used therapeutically by the patient from whom the specimen was taken</span><span> </span><span>— 1</span><span> </span><span>test</span></p><p class="TableText"><span>(Item is subject to rule 6)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>35.05</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66815</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>2 tests described in item 66812</span></p><p class="TableText"><span>(Item is subject to rule 6)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>59.95</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66816</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A test described in item 66812 if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP — 1 test</span></p><p class="TableText"><span>(Item is subject to rules 6, 18 and 18A)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>35.05</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66817</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A test described in item 66812, if rendered by a receiving APP, where 1 or more tests in the item have been rendered by the referring APP</span><span> </span><span>— 1 test</span></p><p class="TableText"><span>(Item is subject to rules 6, 18 and 18A)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>24.90</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66819</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of copper, manganese, selenium or zinc (except if item 66667</span><span style="font-style:italic"> </span><span>applies), in blood, urine or other body fluid</span><span> </span><span>— 1 test</span></p><p class="TableText"><span>(Item is subject to rules 6, 22 and 25)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>30.80</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66820</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A test described in item 66819 if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP — 1 test</span></p><p class="TableText"><span>(Item is subject to rules 6, 18, 18A, 22 and 25)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>30.80</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66821</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A test described in item 66819, if rendered by a receiving APP, where 1 or more tests in the item have been rendered by the referring APP</span><span> </span><span>— 1 test</span></p><p class="TableText"><span>(Item is subject to rules 6, 18, 18A, 22 and 25)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>21.95</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66822</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of copper, manganese, selenium or zinc (except if item 66667 applies), in blood, urine or other body fluid</span><span> </span><span>— 2 or more tests</span></p><p class="TableText"><span>(Item is subject to rules 6, 22 and 25)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>52.80</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66825</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of aluminium (except if item 66671 applies), arsenic, beryllium, cadmium, chromium, gold, mercury, nickel or strontium, in blood, urine or other body fluid or tissue</span><span> </span><span>— 1 test</span></p><p class="TableText"><span>(Item is subject to rules 6,</span><span> </span><span>22 and 25)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>30.80</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66826</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A test described in item 66825 if rendered by a receiving APP where no tests have been rendered by the referring APP — 1 test</span></p><p class="TableText"><span>(Item is subject to rules 6, 18, 18A, 22 and 25 )</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>30.80</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66827</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A test described in item 66825, if rendered by a receiving APP, where 1 or more tests in the item have been rendered by the referring APP</span><span> </span><span>— 1 test</span></p><p class="TableText"><span>(Item is subject to rules 6, 18, 18A, 22 and 25)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>21.95</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66828</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of aluminium (except if item 66671 applies), arsenic, beryllium, cadmium, chromium, gold, mercury, nickel or strontium, in blood, urine or other body fluid or tissue</span><span> </span><span>— 2 or more tests</span></p><p class="TableText"><span>(Item is subject to rules 6,</span><span> </span><span>22 and 25)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>52.80</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66830</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of BNP or NT</span><span>‑</span><span>proBNP for the diagnosis of heart failure in patients presenting with dyspnoea in a hospital Emergency Department</span></p><p class="TableText"><span>(Item is subject to rule 25)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>58.90</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66831</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of copper or iron in liver tissue biopsy</span></p><p class="TableText"><span>(Item is subject to rule 22)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>31.15</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66832</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A test described in item 66831 if rendered by a receiving APP</span></p><p class="TableText"><span>(Item is subject to rules 18A and 22)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>31.15</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66900</span></p></td><td colspan="4" style="width:288.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Carbon</span><span>‑</span><span>labelled urea breath test using oral C</span><span>‑</span><span>13 or C</span><span>‑</span><span>14 urea, including the measurement of exhaled </span><span style="font-size:7.33pt; vertical-align:super">13</span><span>CO</span><span style="font-size:7.33pt; vertical-align:sub">2</span><span> or </span><span style="font-size:7.33pt; vertical-align:super">14</span><span>CO</span><span style="font-size:7.33pt; vertical-align:sub">2</span><span>, (except if item 12533 applies) for:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the confirmation of Helicobactor pylori colonisation; or</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the monitoring of the success of eradication of Helicobactor pylori</span></p><p class="TableP1a"><span>(Item is subject to rule 18)</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>78.15</span></p></td></tr><tr><td colspan="6" style="width:335.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableColHead"><span>Group P3</span><span> </span><span>— Microbiology</span></p></td><td style="width:31.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span></span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69300</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Microscopy of wet film material other than blood, from 1 or more sites, obtained directly from a patient (not cultures) including (if performed):</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>differential cell count; or</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>examination for dermatophytes; or</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>12.60</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span></span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>dark ground illumination; or</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(d)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>stained preparation or preparations using any relevant stain or stains;</span></p><p class="TableText"><span>1 or more tests</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span></span></p></td></tr><tr style="height:88.5pt"><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69303</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Culture and (if performed) microscopy to detect pathogenic micro</span><span>‑</span><span>organisms from nasal swabs, throat swabs, eye swabs and ear swabs (except swabs taken for epidemiological surveillance), including (if performed):</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>pathogen identification and antibiotic susceptibility testing; or</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>22.15</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span></span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a service described in item 69300;</span></p><p class="TableText"><span>specimens from 1 or more sites</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span></span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69306</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Microscopy and culture to detect pathogenic micro</span><span>‑</span><span>organisms from skin or other superficial sites, including (if performed):</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>pathogen identification and antibiotic susceptibility testing; or</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>34.00</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span></span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a service described in items 69300, 69303, 69312 and 69318;</span></p><p class="TableText"><span>1 or more tests on 1 or more specimens</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span></span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69309</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Microscopy and culture to detect dermatophytes and other fungi causing cutaneous disease, from skin scrapings, skin biopsies, hair and nails (excluding swab specimens) and including (if performed):</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the detection of antigens not elsewhere specified in this table; or</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a service described in items 69300, 69303, 69306, 69312 and 69318;</span></p><p class="TableText"><span>1 or more tests on 1 or more specimens</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>48.45</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69312</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Microscopy and culture to detect pathogenic micro</span><span>‑</span><span>organisms from urethra, vagina, cervix or rectum (except for faecal pathogens), including (if performed):</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>pathogen identification and antibiotic susceptibility testing; or</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>34.00</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span></span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a service described in items 69300, 69303, 69306 and 69318;</span></p><p class="TableText"><span>1 or more tests on 1 or more specimens</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span></span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69316</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Detection of Chlamydia trachomatis by any method</span><span> </span><span>— 1 test</span></p><p class="TableText"><span>(Item is subject to rule 26)</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>28.85</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69317</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>This item applies if:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>1 test described in item 69316 is performed; and</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>1 test described in item 69494 is performed</span></p><p class="TableText"><span>(Item is subject to rule 26)</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>36.10</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69318</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Microscopy and culture to detect pathogenic micro</span><span>‑</span><span>organisms from specimens of sputum (except when part of items 69324, 69327 and 69330), including (if performed):</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>pathogen identification and antibiotic susceptibility testing; or</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>34.00</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span></span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a service described in items 69300, 69303, 69306 and 69312;</span></p><p class="TableText"><span>1 or more tests on 1 or more specimens</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span></span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69319</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>This item applies if:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>1 test described in item 69316 is performed; and</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>2 tests described in item 69494 are performed</span></p><p class="TableText"><span>(Item is subject to rule 26)</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>43.25</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69321</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Microscopy and culture of post</span><span>‑</span><span>operative wounds, aspirates of body cavities, synovial fluid, CSF or operative or biopsy specimens, for the presence of pathogenic micro</span><span>‑</span><span>organisms involving aerobic and anaerobic cultures and the use of different culture media, and including (if performed):</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>pathogen identification and antibiotic susceptibility testing; or</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a service described in item 69300, 69303, 69306, 69312 or 69318;</span></p><p class="TableText"><span>specimens from 1 or more sites</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>48.45</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69324</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Microscopy (with appropriate stains) and culture for mycobacteria</span><span> </span><span>— 1</span><span> </span><span>specimen of sputum, urine or other body fluid or 1</span><span> </span><span>operative or biopsy specimen, including (if performed):</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>microscopy and culture of other bacterial pathogens isolated as a result of this procedure; or</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>pathogen identification and antibiotic susceptibility testing;</span></p><p class="TableText"><span>including a service mentioned in item 69300</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>43.30</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69325</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A service described in item 69324 if the microscopy and culture is performed by a receiving APP</span></p><p class="TableText"><span>(Item is subject to rules 18 and 18A)</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>43.30</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69327</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Microscopy (with appropriate stains) and culture for mycobacteria</span><span> </span><span>— 2</span><span> </span><span>specimens of sputum, urine or other body fluids or operative or biopsy specimens, including (if performed):</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>microscopy and culture of other bacterial pathogens isolated as a result of this procedure; or</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>pathogen identification and antibiotic susceptibility testing;</span></p><p class="TableText"><span>including</span><span style="font-weight:bold"> </span><span>a service described in item 69300</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>85.55</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69328</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A service described in item 69327 if the microscopy and culture is performed by a receiving APP</span></p><p class="TableText"><span>(Item is subject to rules 18 and 18A)</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>85.55</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69330</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Microscopy (with appropriate stains) and culture for mycobacteria</span><span> </span><span>— 3</span><span> </span><span>specimens of sputum, urine or other body fluids or operative or biopsy specimens, including (if performed):</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>microscopy and culture of other bacterial pathogens isolated as a result of this procedure; or</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>pathogen identification and antibiotic susceptibility testing;</span></p><p class="TableText"><span>including</span><span style="font-weight:bold"> </span><span>a service described in item 69300</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>128.85</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69331</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A service described in item 69330 if the microscopy and culture is performed by a receiving APP</span></p><p class="TableText"><span>(Item is subject to rules 18 and 18A)</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>128.85</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69333</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Urine examination (including serial examination) by any means other than simple culture by dip slide, including:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>cell count; and</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>culture; and</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>colony count; and</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(d)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>(if performed) stained preparations; and</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(e)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>(if performed) identification of cultured pathogens; and</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>20.70</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span></span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableP1a"><span style="width:9.41pt; text-indent:0pt; display:inline-block"></span><span>(f)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>(if performed) antibiotic susceptibility testing; and</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(g)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>(if performed) examination for pH, specific gravity, blood, albumin, urobilinogen, sugar, acetone or bile salts</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span></span></p></td></tr><tr style="height:71pt"><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69336</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Microscopy of faeces for ova, cysts and parasites, that includes the use of:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a concentration technique; and</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>fixed stains or antigen detection for cryptosporidia and giardia;</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>33.65</span></p></td></tr><tr style="height:49pt"><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span></span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>and includes a service mentioned in item 69300 (if performed)</span></p><p class="TableText"><span>(Item is subject to rule 25)</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span></span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69339</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Microscopy of faeces for ova, cysts and parasites using concentration techniques examined after examination described in item 69336 performed on a separately collected and identified specimen collected within 7</span><span> </span><span>days of the examination described in item 69336</span><span> </span><span>— not more than 1 examination in a 7 day period</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>19.25</span></p></td></tr><tr style="height:89.25pt"><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69345</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Culture and (if performed) microscopy without concentration techniques of faeces for faecal pathogens, using at least 2</span><span> </span><span>selective or enrichment media and culture in at least 2 different atmospheres including (if</span><span> </span><span>performed):</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>pathogen identification and antibiotic susceptibility testing; and</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>53.25</span></p></td></tr><tr style="height:51pt"><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span></span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the detection of clostridial toxins; and</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a service described in item 69300;</span></p><p class="TableText"><span>not more than 1</span><span> </span><span>examination in a 7 day period</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span></span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69354</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Blood culture for pathogenic micro</span><span>‑</span><span>organisms (other than viruses), including sub</span><span>‑</span><span>cultures and (if performed):</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>identification of any cultured pathogen; and</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>necessary antibiotic susceptibility testing;</span></p><p class="TableText"><span>to a maximum of 3 sets of cultures</span><span> </span><span>— 1 set of cultures</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>30.95</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69357</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>2 sets of cultures described in item 69354</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>61.85</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69360</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>3 sets of cultures described in item 69354</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>92.80</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69363</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Detection of Clostridium difficile or Clostridium difficile toxin (except if a service described in item 69345 has been performed)</span><span> </span><span>— 1</span><span> </span><span>or more tests</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>28.85</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69378</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of HIV viral RNA load in plasma or serum in the monitoring of a HIV sero</span><span>‑</span><span>positive patient not on antiretroviral therapy</span><span> </span><span>— 1 or more tests</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>181.45</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69379</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A test described in item 69378 if the quantitation is performed by a receiving APP</span><span> </span><span>— 1 or more tests on 1 or more specimens</span></p><p class="TableText"><span>(Item is subject to rules 18 and 18A)</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>181.45</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69381</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of HIV viral RNA load in plasma or serum in the monitoring of a HIV sero</span><span>‑</span><span>positive patient on antiretroviral therapy</span><span> </span><span>— 1 or more tests on 1</span><span> </span><span>or more specimens</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>181.45</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69382</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of HIV viral RNA load in cerebrospinal fluid in a HIV sero</span><span>‑</span><span>positive patient</span><span> </span><span>— 1 or more tests on 1 or more specimens</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>181.45</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69383</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A test described in item 69381 if the quantitation is performed by a receiving APP</span><span> </span><span>— 1 or more tests on 1</span><span> </span><span>or more specimens</span></p><p class="TableText"><span>(Item is subject to rules 18 and 18A)</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>181.45</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69384</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of 1 antibody to microbial antigens not elsewhere described in this table</span><span> </span><span>— 1</span><span> </span><span>test</span></p><p class="TableText"><span>(Item is subject to rule 6)</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>15.75</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69387</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>2 tests described in item 69384</span></p><p class="TableText"><span>(Item is subject to rule 6)</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>29.20</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69390</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>3 tests described in item 69384</span></p><p class="TableText"><span>(Item is subject to rule 6)</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>42.65</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69393</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>4 tests described in item 69384</span></p><p class="TableText"><span>(Item is subject to rule 6)</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>56.10</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69396</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>5 or more tests described in item 69384</span></p><p class="TableText"><span>(Item is subject to rule 6)</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>69.55</span></p></td></tr><tr style="height:44pt"><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69400</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A test described in item 69384 if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP</span><span> </span><span>— 1 test</span></p><p class="TableText"><span>(Item is subject to rules 6, 18 and 18A)</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>15.75</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69401</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A test described in item 69384 if a referring APP has performed a test or tests described in item 69384</span><span> </span><span>— each test to a maximum of 4 tests</span></p><p class="TableText"><span>(Item is subject to rules 6, 18 and 18A)</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>13.45</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69405</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Microbiological serology during a pregnancy (except in the investigation of a clinically apparent intercurrent microbial illness or close contact with a patient suffering from parvovirus infection or varicella during that pregnancy) including:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the determination of 1 of the following</span><span> </span><span>— rubella immune status, specific syphilis serology, carriage of Hepatitis B, Hepatitis C antibody, HIV antibody; and</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>(if performed) a service described in 1 or more of items 69384, 69475, 69478 and 69481</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>15.75</span></p></td></tr><tr style="height:66.75pt"><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69408</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Microbiological serology during a pregnancy (except in the investigation of a clinically apparent intercurrent microbial illness or close contact with a patient suffering from parvovirus infection or varicella during that pregnancy) including:</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>29.20</span></p></td></tr><tr style="height:35.25pt"><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="page-break-inside:avoid; page-break-after:avoid"><span></span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableP1a" style="page-break-inside:avoid; page-break-after:avoid"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the determination of 2 of the following</span><span> </span><span>— rubella immune status, specific syphilis serology, carriage of Hepatitis B, Hepatitis C antibody, HIV antibody; and</span></p><p class="TableP1a" style="page-break-inside:avoid; page-break-after:avoid"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>(if performed) a service described in 1 or more of items 69384, 69475, 69478 and 69481</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right; page-break-inside:avoid; page-break-after:avoid"><span></span></p></td></tr><tr style="height:62pt"><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69411</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Microbiological serology during a pregnancy (except in the investigation of a clinically apparent intercurrent microbial illness or close contact with a patient suffering from parvovirus infection or varicella during that pregnancy) including:</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>42.65</span></p></td></tr><tr style="height:82pt"><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span></span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the determination of 3 of the following</span><span> </span><span>— rubella immune status, specific syphilis serology, carriage of Hepatitis B, Hepatitis C antibody, HIV antibody; and</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>(if performed) a service described in 1 or more of items 69384, 69475, 69478 and 69481</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span></span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69413</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Microbiological serology during a pregnancy (except in the investigation of a clinically apparent intercurrent microbial illness or close contact with a patient suffering from parvovirus infection or varicella during that pregnancy) including:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the determination of 4 of the following</span><span> </span><span>— rubella immune status, specific syphilis serology, carriage of Hepatitis B, Hepatitis C antibody, HIV antibody; and</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>(if performed) a service described in 1 or more of items 69384, 69475, 69478 and 69481</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>56.10</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69415</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Microbiological serology during a pregnancy (except in the investigation of a clinically apparent intercurrent microbial illness or close contact with a patient suffering from parvovirus infection or varicella during that pregnancy) including:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the determination of all of the following</span><span> </span><span>— rubella immune status, specific syphilis serology, carriage of hepatitis B, hepatitis C antibody, HIV antibody; and</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>(if performed) a service described in 1 or more of items 69384, 69475, 69478 and 69481</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>69.55</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69418</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A test for high risk human papillomaviruses (HPV) in a patient who:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>within the 2 year period before the test, has received excisional or ablative treatment for high grade squamous intraepithelial lesions (HSIL) of the cervix; or</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>64.00</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span></span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>within the 2 year period before the test, has had a positive HPV test after excisional or ablative treatment for HSIL of the cervix; or</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span></span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span></span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>is undergoing annual cytological review following treatment for HSIL of the cervix;</span></p><p class="TableP1a"><span>1 test</span></p><p class="TableText"><span>(Item is subject to rule 25)</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span></span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69419</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A test described in item 69418 if the test is performed by a receiving APP</span><span> </span><span>— 1 test</span></p><p class="TableText"><span>(Item is subject to rules 18, 18A and 25)</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>64.00</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69445</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Detection of hepatitis C viral RNA in a patient undertaking antiviral therapy for chronic HCV hepatitis (including a service described in item 69499)</span><span> </span><span>— 1 test</span></p><p class="TableText"><span>(Item is subject to rule 25)</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>92.80</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69451</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A test described in item 69445 if the test is performed by a receiving APP</span><span> </span><span>— 1 test</span></p><p class="TableText"><span>(Item is subject to rules 18, 18A and 25)</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>92.80</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69471</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Test of cell</span><span>‑</span><span>mediated immunity in blood for the detection of latent tuberculosis in an immunosuppressed or immunocompromised patient</span><span> </span><span>— 1 test</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>35.15</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69472</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Detection of antibodies to Epstein Barr Virus using specific serology</span><span> </span><span>— 1 test</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>15.75</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69474</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Detection of antibodies to Epstein Barr Virus using specific serology</span><span> </span><span>— 2 or more tests</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>28.85</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69475</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Detection of hepatitis antigens or antibodies to determine immune status or viral carriage following exposure or vaccination to Hepatitis A, Hepatitis B, Hepatitis C or Hepatitis D</span><span> </span><span>— 1 test</span></p><p class="TableP1a"><span>(Item is subject to rule 11)</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>15.75</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69478</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>2 tests described in item 69475</span></p><p class="TableText"><span>(Item is subject to rule 11)</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>29.45</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69481</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Investigation of infectious causes of acute or chronic hepatitis</span><span> </span><span>— 3 tests described in item</span><span> </span><span>69475</span></p><p class="TableText"><span>(Item is subject to rule 11)</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>40.80</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69482</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of hepatitis B viral DNA in patients who are hepatitis B surface antigen positive and have chronic hepatitis B but are not receiving antiviral therapy</span><span> </span><span>— 1</span><span> </span><span>test</span></p><p class="TableText"><span>(Item is subject to rule 25)</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>153.10</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69483</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of hepatitis B viral DNA in patients who:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>are hepatitis B surface antigen positive; and</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>have chronic hepatitis B; and</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>are receiving antiviral therapy;</span></p><p class="TableP1a"><span>1 test</span></p><p class="TableText"><span>(Item is subject to rule 25)</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>153.10</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69484</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Supplementary test for hepatitis B surface antigen or hepatitis C antibody using a different assay on a specimen that yielded a reactive result on initial testing</span></p><p class="TableText"><span>(Item is subject to rule 18)</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>17.20</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69488</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of HCV RNA load in plasma or serum in:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the pre</span><span>‑</span><span>treatment evaluation, of </span><span style="font-family:Times, serif">a</span><span> patient with chronic HCV hepatitis, for</span><span style="font-family:Times, serif"> </span><span>antiviral therapy; or</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the assessment of efficacy of antiviral therapy </span><span style="font-family:Times, serif">for</span><span> such a patient;</span></p><p class="TableText"><span>if the test is requested by, or on the advice of, the specialist or consultant physician who manages the treatment of the patient (including a service described in item 69445 or 69499)</span></p><p class="TableText"><span>(Item is subject to rule 25)</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>181.45</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69489</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A test described in item 69488 if the test is performed by a receiving APP</span></p><p class="TableText"><span>(Item is subject to rules 18, 18A and 25)</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>181.45</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="page-break-inside:avoid; page-break-after:avoid"><span>69491</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="page-break-inside:avoid; page-break-after:avoid"><span>Nucleic acid amplification and determination of hepatitis C virus (HCV) genotype if:</span></p><p class="TableP1a" style="page-break-inside:avoid; page-break-after:avoid"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the patient is HCV RNA positive and is being evaluated for antiviral therapy of chronic HCV hepatitis; and</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>206.20</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span></span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the request for the test is made by, or on the advice of, the specialist or consultant physician managing the treatment of the patient</span></p><p class="TableP1a"><span>(Item is subject to rule 25)</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span></span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69492</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A service described in item 69491 if the test is performed by a receiving APP</span></p><p class="TableText"><span>(Item is subject to rules 18, 18A and 25)</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>206.20</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69494</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Detection of a virus, microbial antigen or microbial nucleic acid (not elsewhere described in this table)</span><span> </span><span>— 1</span><span> </span><span>test</span></p><p class="TableText"><span>(Item is subject to rules 6 and 26)</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>28.85</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69495</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>2 tests described in item 69494</span></p><p class="TableText"><span>(Item is subject to rules 6 and 26)</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>36.10</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69496</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>3 or more tests described in item 69494</span></p><p class="TableText"><span>(Item is subject to rules 6 and 26)</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>43.35</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69497</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>This item applies to a test described in item 69494 if:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a referring APP has not performed the test described in item 69494; and</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a receiving APP performs the test described in item 69494;</span></p><p class="TableText"><span>1 test</span></p><p class="TableText"><span>(Item is subject to rules 6, 18, 18A and 26)</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>28.85</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69498</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>This item applies to a test described in item 69494 if:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a referring APP has performed the test or tests described in item 69494; and</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>7.25</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span></span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a receiving APP has performed the test or tests described in item 69494;</span></p><p class="TableText"><span>1 test</span></p><p class="TableText"><span>(Item is subject to rules 6, 18, 18A and 26)</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span></span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="page-break-inside:avoid; page-break-after:avoid"><span>69499</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="page-break-inside:avoid; page-break-after:avoid"><span>Detection of hepatitis C viral RNA if at least 1 of the following criteria is satisfied:</span></p><p class="TableP1a" style="page-break-inside:avoid; page-break-after:avoid"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the patient is hepatitis C sero</span><span>‑</span><span>positive;</span></p><p class="TableP1a" style="page-break-inside:avoid; page-break-after:avoid"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the patient’s serological status is uncertain after testing;</span></p><p class="TableP1a" style="page-break-inside:avoid; page-break-after:avoid"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the test is performed for the purpose of:</span></p><p class="TableP2i" style="page-break-inside:avoid; page-break-after:avoid"><span style="width:25.92pt; text-indent:0pt; display:inline-block"></span><span>(i)</span><span style="width:7.1pt; text-indent:0pt; display:inline-block"> </span><span>determining the hepatitis C status of an immunosuppressed or immunocompromised patient; or</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right; page-break-inside:avoid; page-break-after:avoid"><span>92.80</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span></span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableP2i"><span style="width:22.86pt; text-indent:0pt; display:inline-block"></span><span>(ii)</span><span style="width:7.1pt; text-indent:0pt; display:inline-block"> </span><span>the detection of acute hepatitis C prior to seroconversion where considered necessary for the clinical management of the patient</span></p><p class="TableText"><span>(Item is subject to rules 19 and 25)</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span></span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69500</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A test described in item 69499 if the test is performed by a receiving APP</span></p><p class="TableText"><span>(Item is subject to rules 18, 18A, 19 and 25)</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>92.80</span></p></td></tr><tr><td colspan="7" style="width:377.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableColHead"><span>Group P4</span><span> </span><span>— Immunology</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71057</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Electrophoresis, quantitative and qualitative, of serum, urine or other body fluid all collected within a 28 day period, to demonstrate:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>protein classes; or</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>35.90</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="page-break-inside:avoid"><span></span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>presence and amount of paraprotein;</span></p><p class="TableText" style="page-break-inside:avoid; page-break-after:avoid"><span>including the preliminary quantitation of total protein, albumin and globulin</span><span> </span><span>— 1 specimen type</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right; page-break-inside:avoid; page-break-after:avoid"><span></span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="page-break-inside:avoid"><span>71058</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="page-break-inside:avoid; page-break-after:avoid"><span>Examination as described in item 71057 of 2 or more specimen types</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right; page-break-inside:avoid; page-break-after:avoid"><span>50.85</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71059</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Electrophoresis and immunofixation, immunoelectrophoresis or isoelectric focussing of:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>urine for detection of Bence Jones proteins; or</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>29.40</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span></span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>serum, plasma or other body fluid;</span></p><p class="TableText"><span>and characterisation, if detected, of a paraprotein or cryoglobulin not previously characterised</span><span> </span><span>— examination of 1 specimen type (eg serum, urine or CSF)</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span></span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71060</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Examination as described in item 71059 of 2 or more specimen types</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>44.35</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="page-break-inside:avoid; page-break-after:avoid"><span>71062</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="page-break-inside:avoid; page-break-after:avoid"><span>Electrophoresis and immunofixation or immunoelectrophoresis or isoelectric focussing of CSF for the detection of oligoclonal bands and including if required electrophoresis of the patient’s serum for comparison purposes</span><span> </span><span>— 1 or more tests</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right; page-break-inside:avoid; page-break-after:avoid"><span>44.35</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71064</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Detection and quantitation of cryoglobulins or cryofibrinogen</span><span> </span><span>— 1 or more tests</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>20.90</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71066</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of total immunoglobulin A (by any method) in serum, urine, or other body fluid</span><span> </span><span>— 1 test</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>14.65</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71068</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of total immunoglobulin G (by any method) in serum, urine, or other body fluid</span><span> </span><span>— 1 test</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>14.65</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71069</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>2 tests described in item 71066, 71068, 71072 or 71074</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>22.90</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71071</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>3 or more tests described in item 71066, 71068, 71072 or 71074</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>31.15</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71072</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of total immunoglobulin M (by any method) in serum, urine, or other body fluid</span><span> </span><span>— 1 test</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>14.65</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71073</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of all 4 immunoglobulin G subclasses</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>106.85</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71074</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of total immunoglobulin D (by any method) in serum, urine, or other body fluid</span><span> </span><span>— 1 test</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>14.65</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71075</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of immunoglobulin E (total)</span><span> </span><span>— 1 test</span></p><p class="TableText"><span>(Item is subject to rule 25)</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>23.15</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71076</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A test described in item 71073 if the test is performed by a receiving APP</span><span> </span><span>— 1 test</span></p><p class="TableText"><span>(Item is subject to rules 18 and 18A)</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>106.85</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71077</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of immunoglobulin E (total) in the follow up of a patient with proven immunoglobulin</span><span>‑</span><span>E</span><span>‑</span><span>secreting myeloma, proven congenital immunodeficiency or proven allergic bronchopulmonary aspergillosis</span><span> </span><span>— 1 test</span></p><p class="TableText"><span>(Item is subject to rule 25)</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>27.25</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71079</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Detection of specific immunoglobulin E</span><span> </span><span>antibodies to single or multiple potential allergens</span></p><p class="TableText"><span>(Item is subject to rule 25)</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>27.00</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71081</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of total haemolytic complement</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>40.80</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71083</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of complement components C3 and C4 or properdin factor B</span><span> </span><span>— 1 test</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>20.30</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71085</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>2 tests described in item 71083</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>29.15</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71087</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>3 or more tests described in item 71083</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>37.95</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71089</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of complement components or breakdown products of complement proteins not elsewhere described in an item in this table</span><span> </span><span>— 1 test</span></p><p class="TableText"><span>(Item is subject to rule 6)</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>29.35</span></p></td></tr><tr style="height:44pt"><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71090</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>This item applies to a test described in item 71089 if:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a referring APP has not performed the test described in item 71089; and</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>29.35</span></p></td></tr><tr style="height:64pt"><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span></span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a receiving APP performs the test described in item 71089;</span></p><p class="TableText"><span>1 test</span></p><p class="TableText"><span>(Item is subject to rules 6, 18 and 18A)</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span></span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71091</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>2 tests described in item 71089</span></p><p class="TableText"><span>(Item is subject to rule 6)</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>53.20</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71092</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>This item applies to a test described in item 71089 if:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a referring APP has performed the test or tests described in item 71089; and</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a receiving APP performs the test or tests described in item 71089;</span></p><p class="TableText"><span>1 test</span></p><p class="TableText"><span>(Item is subject to rules 6, 18 and 18A)</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>23.85</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71093</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>3 or more tests described in item 71089</span></p><p class="TableText"><span>(Item is subject to rule 6)</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>76.95</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71095</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of serum or plasma eosinophil cationic protein, or both, to a maximum of 3</span><span> </span><span>assays in 1 year, for monitoring the response to therapy in corticosteroid treated asthma, in a child aged less than 12 years</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>40.80</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71096</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A test described in item 71095 if the quantitation is performed by a receiving APP</span></p><p class="TableText"><span>(Item is subject to rules 18 and 18A)</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>40.80</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71097</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Antinuclear antibodies</span><span> </span><span>— detection in serum or other body fluids, including quantitation if required</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>24.60</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71099</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Double</span><span>‑</span><span>stranded DNA antibodies</span><span> </span><span>— quantitation by 1</span><span> </span><span>or more methods other than the Crithidia method</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>26.70</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71101</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Antibodies to 1 or more extractable nuclear antigens</span><span> </span><span>— detection in serum or other body fluids</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>17.50</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71103</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Characterisation of an antibody detected in a service described in item 71101 (including that service)</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>52.40</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71106</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Rheumatoid factor</span><span> </span><span>— detection by any technique in serum or other body fluids, including quantitation if required</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>11.40</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71119</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Antibodies to tissue antigens not elsewhere specified in this table</span><span> </span><span>— detection, including quantitation if required, of 1</span><span> </span><span>antibody</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>17.45</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71121</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Detection of 2 antibodies specified in item 71119</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>20.95</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71123</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Detection of 3 antibodies specified in item 71119</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>24.40</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71125</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Detection of 4 or more antibodies specified in item</span><span> </span><span>71119</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>27.85</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71127</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Functional tests for lymphocytes</span><span> </span><span>— quantitation, other than by microscopy, of:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>proliferation induced by 1 or more mitogens; or</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>proliferation induced by 1 or more antigens; or</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>177.55</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span></span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>estimation of 1 or more mixed lymphocyte reactions;</span></p><p class="TableText"><span>including a test described in item 65066 or 65070 (if performed)</span></p><p class="TableText"><span>(Item is subject to rule 25)</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span></span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71129</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>2 tests described in item 71127</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>219.30</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71131</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>3 or more tests described in item 71127</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>261.10</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71133</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Investigation of recurrent infection, by qualitative assessment, for the presence of defects in oxidative pathways in neutrophils by the nitroblue tetrazolium (NBT) reduction test</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>10.45</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="page-break-inside:avoid; page-break-after:avoid"><span>71134</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="page-break-inside:avoid; page-break-after:avoid"><span>Investigation of recurrent infection, by quantitative assessment, of oxidative pathways by flow cytometric techniques, including a test described in item 71133 (if</span><span> </span><span>performed)</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>104.75</span></p></td></tr><tr style="height:89pt"><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71135</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of neutrophil function, comprising at least 2 of the following:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>chemotaxis;</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>phagocytosis;</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>oxidative metabolism;</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(d)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>bactericidal activity;</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>209.35</span></p></td></tr><tr style="height:49pt"><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span></span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>including any test described in item 65066, 65070, 71133 or 71134 (if performed)</span></p><p class="TableText"><span>(Item is subject to rule 25)</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span></span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71137</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of cell</span><span>‑</span><span>mediated immunity by multiple antigen delayed type hypersensitivity intradermal skin testing using a minimum of 7</span><span> </span><span>antigens</span></p><p class="TableText"><span>(Item is subject to rule 25)</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>30.45</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71139</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Characterisation of 3 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations, including a total lymphocyte count or total leucocyte count by any method, on 1</span><span> </span><span>or more specimens of blood, CSF or serous fluid</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>104.75</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71141</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Characterisation of 3 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations on 1 or more disaggregated tissue specimens</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>198.70</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71143</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Characterisation of 6 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations for the diagnosis (but not monitoring) of an immunological or haematological malignancy, including a service described in 1 or both of items</span><span> </span><span>71139 and 71141 (if performed), on a specimen of blood, CSF, serous fluid or disaggregated tissue</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>261.75</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="page-break-inside:avoid; page-break-after:avoid"><span>71145</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="page-break-inside:avoid; page-break-after:avoid"><span>Characterisation of 6 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations for the diagnosis (but not monitoring) of an immunological or haematological malignancy, including a service described in 1 or more of items 71139, 71141 and 71143 (if performed) on 2 or more specimens of disaggregated tissues or 1 specimen of disaggregated tissue and 1 or more specimens of blood, CSF or serous fluid</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>427.35</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71146</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Enumeration of CD34+ cells, only for the purposes of autologous or directed allogeneic haemopoietic stem cell transplantation, including a total white cell count on the pheresis collection</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>104.75</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71147</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>HLA</span><span>‑</span><span>B27 typing</span></p><p class="TableText"><span>(Item is subject to rule 27)</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>40.80</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="page-break-inside:avoid; page-break-after:avoid"><span>71148</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="page-break-inside:avoid; page-break-after:avoid"><span>A test described in item 71147 if a receiving APP performs the test</span></p><p class="TableText" style="page-break-inside:avoid; page-break-after:avoid"><span>(Item is subject to rules 18, 18A and 27)</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right; page-break-inside:avoid; page-break-after:avoid"><span>40.80</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71149</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Complete tissue typing for 4 HLA</span><span>‑</span><span>A and HLA</span><span>‑</span><span>B Class</span><span> </span><span>I antigens (including any separation of leucocytes), including (if performed) a service described in item</span><span> </span><span>71147</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>109.00</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71151</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Tissue typing for HLA</span><span>‑</span><span>DR, HLA</span><span>‑</span><span>DP and HLA</span><span>‑</span><span>DQ Class II antigens (including any separation of leucocytes)</span><span> </span><span>— phenotyping or genotyping of 2 or more antigens</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>119.65</span></p></td></tr><tr style="height:123.75pt"><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71153</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Testing, for assessment or diagnosis of systemic inflammatory disease or vasculitis, for the presence of an antibody by 1 of the following tests:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>antineutrophil cytoplasmic antibody (ANCA) immunofluorescence test;</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>antineutrophil proteinase 3 antibody (PR3</span><span> </span><span>ANCA) test;</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>antimyeloperoxidase antibody (MPO</span><span> </span><span>ANCA) test;</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>34.80</span></p></td></tr><tr style="height:43.5pt"><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span></span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(d)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>antiglomerular basement membrane antibody (GBM ANCA) test</span></p><p class="TableText"><span>(Item is subject to rules 6 and 23)</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span></span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71154</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>This item applies to a test described in item 71153 if:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a referring APP has performed a test or tests described in item 71153; and</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>34.80</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span></span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a receiving APP performs the test described in item 71153;</span></p><p class="TableText"><span>1 test</span></p><p class="TableText"><span>(Item is subject to rules 6, 18, 18A and 23)</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span></span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71155</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Testing for the presence of 2 antibodies by tests mentioned in item</span><span> </span><span>71153</span></p><p class="TableText"><span>(Item is subject to rules 6 and 23)</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>47.75</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71156</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>This item applies to a test described in item 71153 (other than a test described in item 71154) if:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a referring APP has performed the test or tests described in item 71153; and</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a receiving APP performs the test or tests described in item 71153;</span></p><p class="TableText"><span>1 test</span></p><p class="TableText"><span>(Item is subject to rules 6, 18, 18A and 23)</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>12.95</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71157</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Testing for the presence of 3 antibodies by tests mentioned in item</span><span> </span><span>71153</span></p><p class="TableText"><span>(Item is subject to rules 6 and 23)</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>60.70</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71159</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Testing for the presence of 4 antibodies by tests mentioned in item</span><span> </span><span>71153</span></p><p class="TableText"><span>(Item is subject to rules 6 and 23)</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>73.65</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71163</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Detection of 1 of the following antibodies (of 1 or more class or isotype) in the assessment or diagnosis of coeliac disease or other gluten hypersensitivity syndromes, including a service described in item 71066 (if performed):</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>antibodies to gliadin;</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>antibodies to endomysium;</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>antibodies to tissue transglutaminase;</span></p><p class="TableP1a"><span>1 test</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>24.90</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71164</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>2 or more tests mentioned in item 71163, including a service described in item 71066 (if performed)</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>40.15</span></p></td></tr><tr style="height:62pt"><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71165</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Antibodies to tissue antigens (acetylcholine receptor, adrenal cortex, heart, histone, insulin, insulin receptor, intrinsic factor, islet cell, lymphocyte, neuron, ovary, parathyroid, platelet, salivary gland, skeletal muscle, skin basement membrane and intercellular substance,</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>34.80</span></p></td></tr><tr style="height:58pt"><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span></span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>thyroglobulin, thyroid microsome or thyroid stimulating hormone receptor)</span><span> </span><span>— detection, including quantitation if required, of 1</span><span> </span><span>antibody</span></p><p class="TableText"><span>(Item is subject to rule 6)</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span></span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71166</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Detection of 2 antibodies described in item 71165</span></p><p class="TableText"><span>(Item is subject to rule 6)</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>47.75</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71167</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Detection of 3 antibodies described in item 71165</span></p><p class="TableText"><span>(Item is subject to rule 6)</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>60.70</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71168</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Detection of 4 or more antibodies described in item</span><span> </span><span>71165</span></p><p class="TableText"><span>(Item is subject to rule 6)</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>73.65</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71169</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>This item applies to a service described in item 71165 if:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a referring APP has not performed the service described in item 71165; and</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a receiving APP performs the service described in item 71165</span></p><p class="TableText"><span>(Item is subject to rules 6, 18 and 18A)</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>34.80</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71170</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>This item applies to a service described in item 71165 if:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a referring APP has performed the test or tests described in item 71165; and</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a receiving APP performs the test or tests described in item 71165;</span></p><p class="TableText"><span>1 test</span></p><p class="TableText"><span>(Item is subject to rules 6, 18 and 18A)</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>12.95</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71180</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Antibody to cardiolipin or beta</span><span>‑</span><span>2 glycoprotein I – detection, including quantitation if required; 1 antibody specificity (IgG or IgM)</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>34.80</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71183</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Detection of 2 antibodies described in item 71180</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>47.75</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71186</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Detection of 3 or more antibodies described in item 71180</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>60.70</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71189</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Detection of specific IgG antibodies to 1 or more respiratory disease allergens not elsewhere specified</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>15.60</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71192</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>2 items described in item 71189</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>28.55</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71195</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>3 or more items described in item 71189</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>40.30</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71198</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Estimation of serum tryptase for the evaluation of unexplained acute hypotension or suspected anaphylactic event, assessment of risk in stinging insect anaphylaxis, exclusion of mastocytosis, monitoring of known mastocytosis</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>40.80</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71200</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Detection and quantitation, if present, of free kappa and lambda light chains in serum for the diagnosis or monitoring of amyloidosis, myeloma or plasma cell dyscrasias</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>35.90</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71203</span></p></td><td colspan="3" style="width:287.4pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Determination of HLAB5701 status by flow cytometry or cytotoxity assay prior to the initiation of Abacavir therapy including item 73323 if performed</span></p></td><td colspan="2" style="width:32.35pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>40.80</span></p></td></tr><tr><td colspan="7" style="width:377.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableColHead"><span>Group P5 — Tissue pathology</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>72813</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Examination of complexity level 2 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions</span><span> </span><span>— 1</span><span> </span><span>or more separately identified specimens</span></p><p class="TableText"><span>(Item is subject to rule 13)</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>72.00</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>72816</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Examination of complexity level 3 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions</span><span> </span><span>— 1</span><span> </span><span>separately identified specimen</span></p><p class="TableText"><span>(Item is subject to rule 13)</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>86.95</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>72817</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Examination of complexity level 3 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions</span><span> </span><span>— 2</span><span> </span><span>to 4 separately identified specimens</span></p><p class="TableText"><span>(Item is subject to rule 13)</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>97.45</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>72818</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Examination of complexity level 3 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions</span><span> </span><span>— 5</span><span> </span><span>or more separately identified specimens</span></p><p class="TableText"><span>(Item is subject to rule 13)</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>107.75</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>72823</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Examination of complexity level 4 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions</span><span> </span><span>— 1</span><span> </span><span>separately identified specimen</span></p><p class="TableText"><span>(Item is subject to rule 13)</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>97.80</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>72824</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Examination of complexity level 4 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions</span><span> </span><span>— 2</span><span> </span><span>to 4 separately identified specimens</span></p><p class="TableText"><span>(Item is subject to rule 13)</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>142.30</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>72825</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Examination of complexity level 4 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions</span><span> </span><span>— 5</span><span> </span><span>to 7 separately identified specimens</span></p><p class="TableText"><span>(Item is subject to rule 13)</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>181.45</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>72826</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Examination of complexity level 4 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions</span><span> </span><span>— 8</span><span> </span><span>to 11 separately identified specimens</span></p><p class="TableText"><span>(Item is subject to rule 13)</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>195.90</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>72827</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Examination of complexity level 4 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions </span><span></span><span>— 12 to 17 separately identified specimens</span></p><p class="TableText"><span>(Item is subject to rule 13)</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>210.35</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>72828</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Examination of complexity level 4 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions</span><span> </span><span>— 18 or more separately identified specimens</span></p><p class="TableText"><span>(Item is subject to rule 13)</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>224.80</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>72830</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Examination of complexity level 5 biopsy material with 1 or more tissue blocks, including specimen dissection,</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>276.00</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span></span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>all tissue processing, staining, light microscopy and professional opinion or opinions</span><span> </span><span>— 1</span><span> </span><span>or more separately identified specimens</span></p><p class="TableText"><span>(Item is subject to rule 13)</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span></span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>72836</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Examination of complexity level 6 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions</span><span> </span><span>— 1</span><span> </span><span>or more separately identified specimens</span></p><p class="TableText"><span>(Item is subject to rule 13)</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>420.00</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>72838</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Examination of complexity level 7 biopsy material with multiple tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy, and professional opinion or opinions</span><span> </span><span>— 1 or more separately identified specimens</span></p><p class="TableText"><span>(Item is subject to rule 13)</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>470.00</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>72844</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Enzyme histochemistry of skeletal muscle for investigation of primary degenerative or metabolic muscle diseases or of muscle abnormalities secondary to disease of the central or peripheral nervous system</span><span> </span><span>— 1 or more tests</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>30.95</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>72846</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Immunohistochemical examination of biopsy material by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen</span><span> </span><span>— 1 to 3 antibodies except those mentioned in item 72848</span></p><p class="TableText"><span>(Item is subject to rule 13)</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>60.00</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>72847</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Immunohistochemical examination of biopsy material by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen</span><span> </span><span>— 4 to 6 antibodies</span></p><p class="TableText"><span>(Item is subject to rule 13)</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>90.00</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>72848</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Immunohistochemical examination of biopsy material by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen</span><span> </span><span>— 1 to 3 of the following antibodies:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>oestrogen;</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>progesterone;</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>c</span><span>‑</span><span>erb</span><span>‑</span><span>B2 (HER2)</span></p><p class="TableText"><span>(Item is subject to rule 13)</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>75.00</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>72849</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Immunohistochemical examination of biopsy material by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen</span><span> </span><span>— 7 to 10 antibodies</span></p><p class="TableText"><span>(Item is subject to rule 13)</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>105.00</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>72850</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Immunohistochemical examination of biopsy material by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen</span><span> </span><span>— 11 or more antibodies</span></p><p class="TableText"><span>(Item is subject to rule 13)</span><span style="width:27.61pt; display:inline-block"></span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>120.00</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>72851</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Electron microscopic examination of biopsy material</span><span> </span><span>— 1</span><span> </span><span>separately identified specimen</span></p><p class="TableText"><span>(Item is subject to rule 13)</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>185.60</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>72852</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Electron microscopic examination of biopsy material</span><span> </span><span>— 2 or more separately identified specimens</span></p><p class="TableText"><span>(Item is subject to rule 13)</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>247.45</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>72855</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Intraoperative consultation and examination of biopsy material by frozen section or tissue imprint or smear</span><span> </span><span>— 1 separately identified specimen</span></p><p class="TableText"><span>(Item is subject to rule 13)</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>185.60</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>72856</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Intraoperative consultation and examination of biopsy material by frozen section or tissue imprint or smear</span><span> </span><span>— 2 to 4 separately identified specimens</span></p><p class="TableText"><span>(Item is subject to rule 13)</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>247.45</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>72857</span></p></td><td colspan="2" style="width:286.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Intraoperative consultation and examination of biopsy material by frozen section or tissue imprint or smear</span><span> </span><span>— 5 or more separately identified specimens</span></p><p class="TableText"><span>(Item is subject to rule 13)</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>288.70</span></p></td></tr><tr><td colspan="7" style="width:377.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableColHead"><span>Group P6</span><span> </span><span>— Cytology</span></p></td></tr><tr><td style="width:32.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73043</span></p></td><td colspan="3" style="width:290.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Cytology (including serial examinations) of nipple discharge or smears from skin, lip, mouth, nose or anus for detection of precancerous or cancerous changes</span><span> </span><span>— 1</span><span> </span><span>or more tests</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>23.00</span></p></td></tr><tr><td style="width:32.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="page-break-inside:avoid; page-break-after:avoid"><span>73045</span></p></td><td colspan="3" style="width:290.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="page-break-inside:avoid; page-break-after:avoid"><span>Cytology (including serial examinations) for malignancy (other than an examination mentioned in item 73053), including any Group P5 service (if performed), 1 or more tests on:</span></p><p class="TableP1a" style="page-break-inside:avoid; page-break-after:avoid"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>specimens resulting from washings or brushings from sites not specified in item</span><span> </span><span>73043; or</span></p><p class="TableP1a" style="page-break-inside:avoid; page-break-after:avoid"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a single specimen of sputum or urine; or</span></p><p class="TableP1a" style="page-break-inside:avoid; page-break-after:avoid"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>1 or more specimens of other body fluids</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right; page-break-inside:avoid; page-break-after:avoid"><span>48.95</span></p></td></tr><tr><td style="width:32.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73047</span></p></td><td colspan="3" style="width:290.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Cytology of a series of 3 sputum or urine specimens for malignant cells</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>95.35</span></p></td></tr><tr><td style="width:32.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73049</span></p></td><td colspan="3" style="width:290.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Cytology of material obtained directly from a patient by fine needle aspiration of solid tissue, or tissues</span><span> </span><span>— 1</span><span> </span><span>identified site</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>68.60</span></p></td></tr><tr><td style="width:32.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73051</span></p></td><td colspan="3" style="width:290.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Cytology of material obtained directly from a patient by fine needle aspiration of solid tissue, or tissues, if:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the aspiration is performed by a recognised pathologist; or</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a recognised pathologist attends the aspiration and performs a cytological examination during the attendance</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>171.50</span></p></td></tr><tr><td style="width:32.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73053</span></p></td><td colspan="3" style="width:290.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Cytology of a smear from cervix, where the smear is prepared by direct application of the specimen to a slide, excluding the use of liquid based slide preparation techniques, and the stained smear is microscopically examined by or on behalf of a pathologist</span><span> </span><span>— each examination:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>for the detection of precancerous or cancerous changes in women with no symptoms, signs or recent history suggestive of cervical neoplasia; or</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>if a further specimen is taken due to an unsatisfactory smear taken for the purposes of paragraph</span><span> </span><span>(a); or</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>if there is inadequate information provided to use item 73055</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>19.60</span></p></td></tr><tr><td style="width:32.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="page-break-inside:avoid; page-break-after:avoid"><span>73055</span></p></td><td colspan="3" style="width:290.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="page-break-inside:avoid; page-break-after:avoid"><span>Cytology of a smear from cervix, not associated with item 73053, where the smear is prepared by direct application of the specimen to a slide, excluding the use of liquid based slide preparation techniques, and the stained smear is microscopically examined by or on behalf of a pathologist</span><span> </span><span>— each test:</span></p><p class="TableP1a" style="page-break-inside:avoid; page-break-after:avoid"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>for the management of previously detected abnormalities including precancerous or cancerous conditions; or</span></p><p class="TableP1a" style="page-break-inside:avoid; page-break-after:avoid"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>for the investigation of women with symptoms, signs or recent history suggestive of cervical neoplasia</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right; page-break-inside:avoid; page-break-after:avoid"><span>19.60</span></p></td></tr><tr style="height:35pt"><td style="width:32.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73057</span></p></td><td colspan="3" style="width:290.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Cytology of a smear from vagina, not associated with item 73053 or 73055, and not to monitor hormone replacement therapy, where the smear is prepared by</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>19.60</span></p></td></tr><tr style="height:24.75pt"><td style="width:32.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span></span></p></td><td colspan="3" style="width:290.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>direct application of the specimen to a slide, excluding the use of liquid based slide preparation techniques, and</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span></span></p></td></tr><tr style="height:30pt"><td style="width:32.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span></span></p></td><td colspan="3" style="width:290.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span></span><span>the stained smear is microscopically examined by or on behalf of a pathologist</span><span> </span><span>— each test</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span></span></p></td></tr><tr><td style="width:32.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73059</span></p></td><td colspan="3" style="width:290.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Immunocytochemical examination of material obtained by procedures described in items 73045, 73047, 73049, 73051, 73062 and 73063 for the characterisation of a malignancy by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen</span><span> </span><span>— 1 to 3 antibodies except those mentioned in item 73061</span></p><p class="TableText"><span>(Item is subject to rule 13)</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>43.30</span></p></td></tr><tr><td style="width:32.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73060</span></p></td><td colspan="3" style="width:290.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Immunocytochemical examination of material obtained by procedures described in items 73045, 73047, 73049, 73051, 73062 and 73063 for the characterisation of a malignancy by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen</span><span> </span><span>—4 to 6 antibodies</span></p><p class="TableText"><span>(Item is subject to rule 13)</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>57.75</span></p></td></tr><tr><td style="width:32.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73061</span></p></td><td colspan="3" style="width:290.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Immunocytochemical examination of material obtained by procedures described in items 73045, 73047, 73049, 73051, 73062 and 73063 for the characterisation of a malignancy by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen</span><span> </span><span>— 1 to 3 of the following antibodies:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>oestrogen;</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>progesterone;</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>c</span><span>‑</span><span>erb</span><span>‑</span><span>B2 (HER2)</span></p><p class="TableText"><span>(Item is subject to rule 13)</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>51.55</span></p></td></tr><tr><td style="width:32.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73062</span></p></td><td colspan="3" style="width:290.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Cytology of material obtained directly from a patient by fine needle aspiration of solid tissue, or tissues</span><span> </span><span>— 2 or more separately identified sites</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>89.60</span></p></td></tr><tr><td style="width:32.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73063</span></p></td><td colspan="3" style="width:290.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Cytology of material obtained directly from a patient by fine needle aspiration of solid tissue, or tissues, if an employee of an approved pathology authority also attends the aspiration for confirmation of sample adequacy</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>100.00</span></p></td></tr><tr><td style="width:32.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73064</span></p></td><td colspan="3" style="width:290.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Immunocytochemical examination of material obtained by procedures described in items 73045, 73047, 73049, 73051, 73062 and 73063 for the characterisation of a malignancy by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen</span><span> </span><span>— 7 to 10 antibodies</span></p><p class="TableText"><span>(Item is subject to rule 13)</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>72.20</span></p></td></tr><tr><td style="width:32.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73065</span></p></td><td colspan="3" style="width:290.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Immunocytochemical examination of material obtained by procedures described in items 73045, 73047, 73049, 73051, 73062 and 73063 for the characterisation of a malignancy by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen</span><span> </span><span>— 11 or more antibodies</span></p><p class="TableText"><span>(Item is subject to rule 13)</span></p></td><td colspan="3" style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>89.60</span></p></td></tr><tr><td colspan="7" style="width:377.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableColHead"><span>Group P7 — Genetics</span></p></td></tr><tr><td style="width:32.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73287</span></p></td><td colspan="2" style="width:289.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Study of the whole of every chromosome by cytogenetics or other techniques, performed on 1 or more of any tissue or fluid except blood (including a service mentioned in item 73293, if performed)</span><span> </span><span>— 1</span><span> </span><span>or</span><span> </span><span>more tests</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>397.20</span></p></td></tr><tr><td style="width:32.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73289</span></p></td><td colspan="2" style="width:289.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Study of the whole of every chromosome by cytogenetics or other techniques, performed on blood (including a service mentioned in item 73294, if performed)</span><span> </span><span>— 1 or more tests</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>361.35</span></p></td></tr><tr><td style="width:32.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73290</span></p></td><td colspan="2" style="width:289.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Study of the whole of every chromosome by cytogenetics or other techniques, performed on blood or bone marrow, to diagnose or monitor haematological malignancy (including a service mentioned in item 73287 or 73289, if performed)</span><span> </span><span>— 1</span><span> </span><span>or</span><span> </span><span>more tests</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>397.20</span></p></td></tr><tr><td style="width:32.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73291</span></p></td><td colspan="2" style="width:289.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Analysis of 1 or more chromosome regions, performed on blood or fresh tissue, for specific constitutional genetic abnormalities in:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>diagnostic studies of a person with developmental delay, intellectual disability, autism, or at least 2 congenital abnormalities, in whom a study by cytogenetics or other techniques mentioned in item 73287 or 73289 is normal or has not been performed</span><span> </span><span>— 1</span><span> </span><span>or</span><span> </span><span>more tests; or</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>studies of a relative of the person for an abnormality previously identified in the person</span><span> </span><span>— 1</span><span> </span><span>or</span><span> </span><span>more tests</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>232.50</span></p></td></tr><tr><td style="width:32.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73292</span></p></td><td colspan="2" style="width:289.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Analysis of chromosomes by genome-wide microarray, including targeted assessment of specific regions for constitutional genetic abnormalities in diagnostic studies of a person with developmental delay, intellectual disability, autism, or at least 2 congenital abnormalities (including a service mentioned in item 73287, 73289 or 73291, if performed)</span><span> </span><span>— 1</span><span> </span><span>or</span><span> </span><span>more tests</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>593.85</span></p></td></tr><tr><td style="width:32.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73293</span></p></td><td colspan="2" style="width:289.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Analysis of 1 or more regions on all chromosomes, performed on fresh tissue, for specific constitutional genetic abnormalities in diagnostic studies of the products of conception, including exclusion of maternal cell contamination</span><span> </span><span>— 1</span><span> </span><span>or</span><span> </span><span>more tests</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>232.50</span></p></td></tr><tr><td style="width:32.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73294</span></p></td><td colspan="2" style="width:289.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Analysis of the PMP22 gene for constitutional genetic abnormalities causing peripheral neuropathy, as:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>diagnostic studies of a person with peripheral neuropathy</span><span> </span><span>— 1</span><span> </span><span>or</span><span> </span><span>more tests; or</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>studies of a relative of the person for an abnormality previously identified in the person</span><span> </span><span>— 1</span><span> </span><span>or</span><span> </span><span>more tests</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>232.50</span></p></td></tr><tr><td style="width:32.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73300</span></p></td><td colspan="2" style="width:289.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Detection of mutation of the FMR1 gene if:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the patient exhibits intellectual disability, ataxia, neurodegeneration, or premature ovarian failure consistent with an FMR1 mutation; or</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the patient has a relative with an FMR1 mutation;</span></p><p class="TableText"><span>1 or more tests</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>102.00</span></p></td></tr><tr><td style="width:32.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73305</span></p></td><td colspan="2" style="width:289.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Detection of a mutation of the FMR1 gene by Southern Blot analysis, if the results of a service performed in item 73300 are inconclusive</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>204.00</span></p></td></tr><tr><td style="width:32.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73308</span></p></td><td colspan="2" style="width:289.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Characterisation of the genotype of a patient for Factor</span><span> </span><span>V Leiden gene mutation, or detection of other relevant mutations in the investigation of proven venous thrombosis or pulmonary embolism</span><span> </span><span>— 1 or more tests</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>36.70</span></p></td></tr><tr><td style="width:32.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73309</span></p></td><td colspan="2" style="width:289.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A test described in item 73308 if the test is performed by a receiving APP</span><span> </span><span>— 1 or more tests</span></p><p class="TableText"><span>(Item is subject to rules 18 and 18A)</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>36.70</span></p></td></tr><tr><td style="width:32.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73311</span></p></td><td colspan="2" style="width:289.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Characterisation of the genotype of a person who is a first degree relative of a person who has been proven to have 1 or more abnormal genotypes under item</span><span> </span><span>73308</span><span> </span><span>— 1 or more tests</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>36.70</span></p></td></tr><tr><td style="width:32.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73312</span></p></td><td colspan="2" style="width:289.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A test described in item 73311 if the test is performed by a receiving APP</span><span> </span><span>— 1 or more tests</span></p><p class="TableText"><span>(Item is subject to rules 18 and 18A)</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>36.70</span></p></td></tr><tr><td style="width:32.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="page-break-inside:avoid; page-break-after:avoid"><span>73314</span></p></td><td colspan="2" style="width:289.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="page-break-inside:avoid; page-break-after:avoid"><span>Characterisation of gene rearrangement or the identification of mutations within a known gene rearrangement in the diagnosis and monitoring of patients with laboratory evidence of:</span></p><p class="TableP1a" style="page-break-inside:avoid; page-break-after:avoid"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>acute myeloid leukaemia; or</span></p><p class="TableP1a" style="page-break-inside:avoid; page-break-after:avoid"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>acute promyelocytic leukaemia; or</span></p><p class="TableP1a" style="page-break-inside:avoid; page-break-after:avoid"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>acute lymphoid leukaemia; or</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right; page-break-inside:avoid; page-break-after:avoid"><span>232.50</span></p></td></tr><tr><td style="width:32.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span></span></p></td><td colspan="2" style="width:289.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(d)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>chronic myeloid leukaemia</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span></span></p></td></tr><tr><td style="width:32.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73315</span></p></td><td colspan="2" style="width:289.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A service described in item 73314 if the characterisation is performed by a receiving APP</span><span> </span><span>— 1</span><span> </span><span>or more tests</span></p><p class="TableText"><span>(Item is subject to rules 18 and 18A)</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>232.50</span></p></td></tr><tr><td style="width:32.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73317</span></p></td><td colspan="2" style="width:289.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Detection of the C282Y genetic mutation of the HFE gene and, if performed, detection of other mutations for haemochromatosis </span><span style="font-size:12pt">where:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the patient has an elevated transferrin saturation or elevated serum ferritin on testing of repeated specimens; or</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the patient has a first degree relative with haemochromatosis; or</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the patient has a first degree relative with homozygosity for the C282Y genetic mutation, or with compound heterozygosity for recognised genetic mutations for haemochromatosis</span></p><p class="TableText"><span>(Item is subject to rule 20)</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>36.70</span></p></td></tr><tr><td style="width:32.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73318</span></p></td><td colspan="2" style="width:289.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A test described in item 73317 if the detection is performed by a receiving APP</span><span> </span><span>— 1 or more tests</span></p><p class="TableText"><span>(Item is subject to rules 18, 18A and 20)</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>36.70</span></p></td></tr><tr><td style="width:32.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73320</span></p></td><td colspan="2" style="width:289.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Detection of HLA</span><span>‑</span><span>B27 by nucleic acid amplification including a service described in item 71147 unless the service in this item is rendered as a pathologist</span><span>‑</span><span>determinable service</span></p><p class="TableText"><span>(Item is subject to rule 27)</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>40.80</span></p></td></tr><tr><td style="width:32.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73321</span></p></td><td colspan="2" style="width:289.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A test described in item 73320 if the detection is performed by a receiving APP</span><span> </span><span>— 1 or more tests</span></p><p class="TableText"><span>(Item is subject to rules 18, 18A and 27)</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>40.80</span></p></td></tr><tr><td style="width:32.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73323</span></p></td><td colspan="2" style="width:289.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Determination of HLAB5701 status by molecular techniques prior to the initiation of Abacavir therapy including item 71203 if performed</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>40.80</span></p></td></tr><tr><td style="width:32.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73324</span></p></td><td colspan="2" style="width:289.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A test described in item 73323 if rendered by a receiving APP</span><span> </span><span>— 1 or more tests</span></p><p class="TableText"><span>(Item is subject to Rule 18)</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>41.25</span></p></td></tr><tr><td colspan="7" style="width:377.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableColHead"><span>Group P8 — Infertility and pregnancy tests</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73521</span></p></td><td style="width:285.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Semen examination for presence of spermatozoa or examination of cervical mucus for spermatozoa (Huhner’s test)</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>9.75</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73523</span></p></td><td style="width:285.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Semen examination (other than post</span><span>‑</span><span>vasectomy semen examination), including:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>measurement of volume, sperm count and motility; and</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>examination of stained preparations; and</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>morphology; and</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(d)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>(if performed) differential count and 1 or more chemical tests</span></p><p class="TableText"><span>(Item is subject to rule 25)</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>42.05</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73525</span></p></td><td style="width:285.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Sperm antibodies</span><span> </span><span>— sperm</span><span>‑</span><span>penetrating ability</span><span> </span><span>— 1</span><span> </span><span>or</span><span> </span><span>more tests</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>28.55</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="page-break-inside:avoid; page-break-after:avoid"><span>73527</span></p></td><td style="width:285.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="page-break-inside:avoid; page-break-after:avoid"><span>Human chorionic gonadotrophin (HCG)</span><span> </span><span>— detection in serum or urine by 1 or more methods for diagnosis of pregnancy</span><span> </span><span>— 1</span><span> </span><span>or more tests</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right; page-break-inside:avoid; page-break-after:avoid"><span>10.05</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="page-break-inside:avoid; page-break-after:avoid"><span>73529</span></p></td><td style="width:285.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="page-break-inside:avoid; page-break-after:avoid"><span>Human chorionic gonadotrophin (HCG), quantitation in serum by 1 or more methods (except by latex, membrane, strip or other pregnancy test kit) for diagnosis of threatened abortion, or follow up of abortion or diagnosis of ectopic pregnancy, including any services performed in item 73527</span><span> </span><span>— 1 test</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right; page-break-inside:avoid; page-break-after:avoid"><span>28.85</span></p></td></tr><tr><td colspan="7" style="width:377.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableColHead"><span>Group P9 — Simple basic pathology tests</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73801</span></p></td><td style="width:285.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Semen examination for presence of spermatozoa</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>6.95</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73802</span></p></td><td style="width:285.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Leucocyte count, erythrocyte sedimentation rate, examination of blood film (including differential leucocyte count), haemoglobin, haematocrit or erythrocyte count</span><span> </span><span>— 1 test</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>4.60</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73803</span></p></td><td style="width:285.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>2 tests described in item 73802</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>6.40</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73804</span></p></td><td style="width:285.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>3 or more tests described in item 73802</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>8.20</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73805</span></p></td><td style="width:285.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Microscopy of urine, whether stained or not, or catalase test</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>4.60</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73806</span></p></td><td style="width:285.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Pregnancy test by 1 or more immunochemical methods</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>10.20</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73807</span></p></td><td style="width:285.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Microscopy for wet film other than urine, including any relevant stain</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>6.95</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73808</span></p></td><td style="width:285.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Microscopy of Gram</span><span>‑</span><span>stained film, including (if performed) a service described in item 73805 or 73807</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>8.70</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73809</span></p></td><td style="width:285.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Chemical tests for occult blood in faeces by reagent stick, strip, tablet or similar method</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>2.35</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73810</span></p></td><td style="width:285.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Microscopy for fungi in skin, hair or nails</span><span> </span><span>— 1 or more sites</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>6.95</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73811</span></p></td><td style="width:285.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Mantoux test</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>11.30</span></p></td></tr><tr><td colspan="7" style="width:377.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableColHead"><span>Group P10 — Patient episode initiation</span></p></td></tr><tr><td colspan="7" style="width:377.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="Note" style="margin-left:0pt"><span style="font-style:italic">Note</span><span style="font-style:italic"> </span><span style="font-style:italic"></span><span style="font-style:italic"></span><span>Items 73922 to 73927 in Subgroup 1 apply to the initiation of a patient episode consisting of a service described in a particular item in the table. If the initiation of the patient episode consists of a service described in an item other than those particular services, an item mentioned in Subgroup 2 will apply to the patient episode.</span></p></td></tr><tr><td colspan="7" style="width:377.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="ColHead2"><span>Subgroup 1</span><span> </span><span>— Initiation of a patient episode involving particular services</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73920</span></p></td><td style="width:285.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Initiation of a patient episode by collection of a specimen for 1</span><span> </span><span>or more services (other than those described in item 73922, 73924 or 73926) if the specimen is collected in an approved collection centre that the approved pathology authority operates in the same premises as it operates a category GX or GY pathology laboratory</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>2.40</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73922</span></p></td><td style="width:285.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Initiation of a patient episode that consists of a service described in item 73053, 73055 or 73057 (in circumstances other than those described in item</span><span> </span><span>73923)</span></p><p class="TableText"><span>(Item is subject to rule 14)</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>8.25</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73923</span></p></td><td style="width:285.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Initiation of a patient episode that consists of a service described in item 73053, 73055 or 73057 if:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the person is a private patient in a recognised hospital; or</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the person receives the service from a prescribed laboratory</span></p><p class="TableP1a"><span>(Item is subject to rule 14)</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>2.40</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73924</span></p></td><td style="width:285.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Initiation of a patient episode that consists of 1 or more services described in items 72813, 72816, 72817, 72818, 72823, 72824, 72825, 72826, 72830 and 72836 (in circumstances other than those described in item</span><span> </span><span>73925) from a person who is an in</span><span>‑</span><span>patient of a hospital</span></p><p class="TableText"><span>(Item is subject to rule 14)</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>14.75</span></p></td></tr><tr style="height:70.5pt"><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73925</span></p></td><td style="width:285.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Initiation of a patient episode that consists of 1 or more services described in items 72813, 72816, 72817, 72818, 72823, 72824, 72825, 72826, 72830 and 72836 if the person is:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a private patient of a recognised hospital; or</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>2.40</span></p></td></tr><tr style="height:39.75pt"><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span></span></p></td><td style="width:285.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a private patient of a hospital who receives the service or services from a prescribed laboratory</span></p><p class="TableP1a"><span>(Item is subject to rule 14)</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span></span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73926</span></p></td><td style="width:285.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Initiation of a patient episode that consists only of 1 or more services described in items 72813, 72816, 72817, 72818, 72823, 72824, 72825, 72826, 72830 and 72836 (in circumstances other than those described in item 73927) from a person who is not a patient of a hospital</span></p><p class="TableText"><span>(Item is subject to rule 14)</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>8.25</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73927</span></p></td><td style="width:285.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Initiation of a patient episode by a prescribed laboratory that consists of 1 or more services described in items</span><span> </span><span>72813, 72816, 72817, 72818, 72823, 72824, 72825, 72826, 72830 and 72836 from a person who is not a patient of a hospital</span></p><p><span>(Item is subject to rule 14)</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>2.40</span></p></td></tr><tr><td colspan="7" style="width:377.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="ColHead2"><span>Subgroup 2</span><span> </span><span>— Initiation of a patient episode involving other services</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73928</span></p></td><td style="width:285.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Initiation of a patient episode by collection of a specimen for 1</span><span> </span><span>or more services (in circumstances other than those described in item 73920, 73922, 73923, 73924, 73925, 73926, 73927 or 73929) if the specimen is collected in an approved collection centre</span></p><p class="TableText"><span>(Item is subject to rule 14)</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>6.00</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73929</span></p></td><td style="width:285.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Initiation of a patient episode by collection of a specimen for 1</span><span> </span><span>or more services (in circumstances other than those described in item 73922, 73923, 73924, 73925, 73926 or 73927) if the specimen is collected in an approved collection centre by:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>an approved pathology practitioner of a prescribed laboratory; or</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>2.40</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span></span></p></td><td style="width:285.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>an employee of an approved pathology authority of a prescribed laboratory</span></p><p class="TableText"><span>(Item is subject to rule 14)</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span></span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73930</span></p></td><td style="width:285.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Initiation of a patient episode by collection of a specimen for 1</span><span> </span><span>or more services (in circumstances other than those described in item 73922, 73923, 73924, 73925, 73926, 73927 or 73931) if the specimen is collected from a person who is an in</span><span>‑</span><span>patient of a hospital other than a recognised hospital by an approved pathology practitioner or an employee of an approved pathology authority</span></p><p class="TableText"><span>(Item is subject to rule 14)</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>6.00</span></p></td></tr><tr style="height:142.5pt"><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73931</span></p></td><td style="width:285.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Initiation of a patient episode by collection of a specimen for 1</span><span> </span><span>or more services (in circumstances other than those described in item 73922, 73923, 73924, 73925, 73926 or 73927) if the specimen is collected:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>from a person who is a private patient of a hospital by an approved pathology practitioner of a prescribed laboratory; or</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>from a person who is a private patient of a hospital by an employee of an approved pathology authority that operates a prescribed laboratory; or</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>2.40</span></p></td></tr><tr style="height:105.75pt"><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span></span></p></td><td style="width:285.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>from a person who is a private patient of a recognised hospital by an approved pathology practitioner of an approved pathology authority; or</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(d)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>from a person who is a private patient of a recognised hospital by an employee of an approved pathology authority</span></p><p class="TableP1a"><span>(Item is subject to rule 14)</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span></span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73932</span></p></td><td style="width:285.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Initiation of a patient episode by collection of a specimen for 1</span><span> </span><span>or more services (in circumstances other than those described in item 73922, 73923, 73924, 73925, 73926, 73927 or 73933) if the specimen is collected from a person in the place where the person resides, and that place is not an institution, by:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>an approved pathology practitioner of an approved pathology authority; or</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>10.30</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span></span></p></td><td style="width:285.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>an employee of an approved pathology authority</span></p><p class="TableText"><span>(Item is subject to rule 14)</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span></span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73933</span></p></td><td style="width:285.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Initiation of a patient episode by collection of a specimen for 1</span><span> </span><span>or more services (in circumstances other than those described in item 73922, 73923, 73924, 73925, 73926 or 73927) if the specimen is collected from a person in the place where the person resides, and that place is not an institution, by:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>an approved pathology practitioner of a prescribed laboratory; or</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>an employee of an approved pathology authority that operates a prescribed laboratory</span></p><p class="TableP1a"><span>(Item is subject to rule 14)</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>2.40</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73934</span></p></td><td style="width:285.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Initiation of a patient episode by collection of a specimen for 1</span><span> </span><span>or more services (in circumstances other than those described in item 73922, 73923, 73924, 73925, 73926, 73927 or 73935) if the specimen is collected from a person in an institution by:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>an approved pathology practitioner; or</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>an employee of an approved pathology authority</span></p><p class="TableP1a"><span>(Item is subject to rule 14)</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>17.70</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="page-break-inside:avoid; page-break-after:avoid"><span>73935</span></p></td><td style="width:285.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="page-break-inside:avoid; page-break-after:avoid"><span>Initiation of a patient episode by collection of a specimen for 1</span><span> </span><span>or more services (in circumstances other than those described in item 73922, 73923, 73924, 73925, 73926 or 73927) if the specimen is collected from a person in an institution by:</span></p><p class="TableP1a" style="page-break-inside:avoid; page-break-after:avoid"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>an approved pathology practitioner of a prescribed laboratory; or</span></p><p class="TableP1a" style="page-break-inside:avoid; page-break-after:avoid"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>an employee of an approved pathology authority that operates a prescribed laboratory</span></p><p class="TableP1a" style="page-break-inside:avoid; page-break-after:avoid"><span>(Item is subject to rule 14)</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right; page-break-inside:avoid; page-break-after:avoid"><span>2.40</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73936</span></p></td><td style="width:285.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Initiation of a patient episode by collection of a specimen for 1</span><span> </span><span>or more services (in circumstances other than those described in item 73922, 73923, 73924, 73925, 73926, 73927 or 73937) if the specimen is collected from the person by the person</span></p><p class="TableText"><span>(Item is subject to rule 14)</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>6.00</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73937</span></p></td><td style="width:285.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Initiation of a patient episode by collection of a specimen for 1</span><span> </span><span>or more services (in circumstances other than those described in item 73922, 73923, 73924, 73925, 73926 or 73927) if the specimen is collected from the person by the person, and:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the service is performed in a prescribed laboratory; or</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the person is a private patient in a recognised hospital</span></p><p class="TableP1a"><span>(Item is subject to rule 14)</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>2.40</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73938</span></p></td><td style="width:285.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Initiation of a patient episode by collection of a specimen for 1</span><span> </span><span>or more services (in circumstances other than those described in items 73922, 73923, 73924, 73925, 73926, 73927 or 73939) if the specimen is collected by, or on behalf of, the treating practitioner</span></p><p class="TableText"><span>(Item is subject to rule 14)</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>8.00</span></p></td></tr><tr style="height:59.25pt"><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="page-break-inside:avoid"><span>73939</span></p></td><td style="width:285.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="page-break-inside:avoid"><span>Initiation of a patient episode by collection of a specimen for 1</span><span> </span><span>or more services (in circumstances other than those described in item 73922, 73923, 73924, 73925, 73926 or 73927) if the specimen is collected by, or on behalf of, the treating practitioner and:</span></p><p class="TableP1a" style="page-break-inside:avoid"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the service is performed in a prescribed laboratory; or</span></p><p class="TableP1a" style="page-break-inside:avoid"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the person is a private patient in a recognised hospital</span></p><p class="TableText" style="page-break-inside:avoid"><span>(Item is subject to rule 14)</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right; page-break-inside:avoid"><span>2.40</span></p></td></tr><tr style="height:19.85pt"><td colspan="7" style="width:377.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableColHead"><span>Group P11 — Specimen referred</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73940</span></p></td><td style="width:285.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Receipt of a specimen by an approved pathology practitioner of an approved pathology authority from another approved pathology practitioner of another approved pathology authority</span></p><p class="TableText"><span>(Item is subject to rules 14, 15 and 16)</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>10.30</span></p></td></tr><tr><td colspan="7" style="width:377.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableColHead"><span>Group P12</span><span> </span><span>— Management of bulk</span><span>‑</span><span>billed services</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>74990</span></p></td><td style="width:285.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A pathology service to which an item in this table (other than this item or item 74991) applies if:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the service is an unreferred service; and</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the service is provided to a person who is under the age of 16 or is a Commonwealth concession card holder; and</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the person is not an admitted patient of a hospital; and</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(d)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the service is bulk</span><span>‑</span><span>billed in respect of the fees for:</span></p><p class="TableP2i"><span style="width:25.92pt; text-indent:0pt; display:inline-block"></span><span>(i)</span><span style="width:7.1pt; text-indent:0pt; display:inline-block"> </span><span>this item; and</span></p><p class="TableP2i"><span style="width:22.86pt; text-indent:0pt; display:inline-block"></span><span>(ii)</span><span style="width:7.1pt; text-indent:0pt; display:inline-block"> </span><span>the other item in this table applying to the service</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>6.20</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>74991</span></p></td><td style="width:285.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A pathology service to which an item in this table (other than this item or item 74990) applies if:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the service is an unreferred service; and</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the service is provided to a person who is under the age of 16 or is a Commonwealth concession card holder; and</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the person is not an admitted patient of a hospital; and</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(d)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the service is bulk</span><span>‑</span><span>billed in respect of the fees for:</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>9.40</span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span></span></p></td><td style="width:285.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableP2i"><span style="width:25.92pt; text-indent:0pt; display:inline-block"></span><span>(i)</span><span style="width:7.1pt; text-indent:0pt; display:inline-block"> </span><span>this item; and</span></p><p class="TableP2i"><span style="width:22.86pt; text-indent:0pt; display:inline-block"></span><span>(ii)</span><span style="width:7.1pt; text-indent:0pt; display:inline-block"> </span><span>the other item in this table applying to the service; and</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span></span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span></span></p></td><td style="width:285.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(e)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the service is provided at, or from, a practice location in:</span></p><p class="TableP2i"><span style="width:25.92pt; text-indent:0pt; display:inline-block"></span><span>(i)</span><span style="width:7.1pt; text-indent:0pt; display:inline-block"> </span><span>a regional, rural or remote area; or</span></p><p class="TableP2i"><span style="width:22.86pt; text-indent:0pt; display:inline-block"></span><span>(ii)</span><span style="width:7.1pt; text-indent:0pt; display:inline-block"> </span><span>Tasmania; or</span></p><p class="TableP2i"><span style="width:19.81pt; text-indent:0pt; display:inline-block"></span><span>(iii)</span><span style="width:7.1pt; text-indent:0pt; display:inline-block"> </span><span>a geographical area included in any of the following SSD spatial units:</span></p><p class="P3" style="margin-top:0pt; margin-left:72.6pt; text-indent:-72.6pt"><span style="width:45.38pt; text-indent:0pt; font-size:11pt; display:inline-block"></span><span style="font-size:11pt">(A)</span><span style="width:7.9pt; text-indent:0pt; font-size:11pt; display:inline-block"> </span><span style="font-size:11pt">Beaudesert Shire Part A;</span></p><p class="P3" style="margin-top:0pt; margin-left:72.6pt; text-indent:-72.6pt"><span style="width:45.99pt; text-indent:0pt; font-size:11pt; display:inline-block"></span><span style="font-size:11pt">(B)</span><span style="width:7.9pt; text-indent:0pt; font-size:11pt; display:inline-block"> </span><span style="font-size:11pt">Belconnen;</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span></span></p></td></tr><tr style="height:48.75pt"><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span></span></p></td><td style="width:285.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="P3" style="margin-top:0pt; margin-left:72.6pt; text-indent:-72.6pt"><span style="width:45.99pt; text-indent:0pt; font-size:11pt; display:inline-block"></span><span style="font-size:11pt">(C)</span><span style="width:7.9pt; text-indent:0pt; font-size:11pt; display:inline-block"> </span><span style="font-size:11pt">Darwin City;</span></p><p class="P3" style="margin-top:0pt; margin-left:72.6pt; text-indent:-72.6pt"><span style="width:45.38pt; text-indent:0pt; font-size:11pt; display:inline-block"></span><span style="font-size:11pt">(D)</span><span style="width:7.9pt; text-indent:0pt; font-size:11pt; display:inline-block"> </span><span style="font-size:11pt">Eastern Outer Melbourne;</span></p><p class="P3" style="margin-top:0pt; margin-left:72.6pt; text-indent:-72.6pt"><span style="width:46.6pt; text-indent:0pt; font-size:11pt; display:inline-block"></span><span style="font-size:11pt">(E)</span><span style="width:7.9pt; text-indent:0pt; font-size:11pt; display:inline-block"> </span><span style="font-size:11pt">East Metropolitan;</span></p><p class="P3" style="margin-top:0pt; margin-left:72.6pt; text-indent:-72.6pt"><span style="width:47.21pt; text-indent:0pt; font-size:11pt; display:inline-block"></span><span style="font-size:11pt">(F)</span><span style="width:7.9pt; text-indent:0pt; font-size:11pt; display:inline-block"> </span><span style="font-size:11pt">Frankston City;</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span></span></p></td></tr><tr><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span></span></p></td><td style="width:285.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="P3" style="margin-top:0pt; margin-left:72.6pt; text-indent:-72.6pt"><span style="width:45.38pt; text-indent:0pt; font-size:11pt; display:inline-block"></span><span style="font-size:11pt">(G)</span><span style="width:7.9pt; text-indent:0pt; font-size:11pt; display:inline-block"> </span><span style="font-size:11pt">Gosford</span><span style="font-size:11pt">‑</span><span style="font-size:11pt">Wyong;</span></p><p class="P3" style="margin-top:0pt; margin-left:72.6pt; text-indent:-72.6pt"><span style="width:45.38pt; text-indent:0pt; font-size:11pt; display:inline-block"></span><span style="font-size:11pt">(H)</span><span style="width:7.9pt; text-indent:0pt; font-size:11pt; display:inline-block"> </span><span style="font-size:11pt">Greater Geelong City Part A;</span></p><p class="P3" style="margin-top:0pt; margin-left:72.6pt; text-indent:-72.6pt"><span style="width:49.66pt; text-indent:0pt; font-size:11pt; display:inline-block"></span><span style="font-size:11pt">(I)</span><span style="width:7.9pt; text-indent:0pt; font-size:11pt; display:inline-block"> </span><span style="font-size:11pt">Gungahlin</span><span style="font-size:11pt">‑</span><span style="font-size:11pt">Hall;</span></p><p class="P3" style="margin-top:0pt; margin-left:72.6pt; text-indent:-72.6pt"><span style="width:49.04pt; text-indent:0pt; font-size:11pt; display:inline-block"></span><span style="font-size:11pt">(J)</span><span style="width:7.9pt; text-indent:0pt; font-size:11pt; display:inline-block"> </span><span style="font-size:11pt">Ipswich City (Part in BSD);</span></p><p class="P3" style="margin-top:0pt; margin-left:72.6pt; text-indent:-72.6pt"><span style="width:45.38pt; text-indent:0pt; font-size:11pt; display:inline-block"></span><span style="font-size:11pt">(K)</span><span style="width:7.9pt; text-indent:0pt; font-size:11pt; display:inline-block"> </span><span style="font-size:11pt">Litchfield Shire;</span></p><p class="P3" style="margin-top:0pt; margin-left:72.6pt; text-indent:-72.6pt"><span style="width:46.6pt; text-indent:0pt; font-size:11pt; display:inline-block"></span><span style="font-size:11pt">(L)</span><span style="width:7.9pt; text-indent:0pt; font-size:11pt; display:inline-block"> </span><span style="font-size:11pt">Melton</span><span style="font-size:11pt">‑</span><span style="font-size:11pt">Wyndham;</span></p><p class="P3" style="margin-top:0pt; margin-left:72.6pt; text-indent:-72.6pt"><span style="width:43.54pt; text-indent:0pt; font-size:11pt; display:inline-block"></span><span style="font-size:11pt">(M)</span><span style="width:7.9pt; text-indent:0pt; font-size:11pt; display:inline-block"> </span><span style="font-size:11pt">Mornington Peninsula Shire;</span></p><p class="P3" style="margin-top:0pt; margin-left:72.6pt; text-indent:-72.6pt"><span style="width:45.38pt; text-indent:0pt; font-size:11pt; display:inline-block"></span><span style="font-size:11pt">(N)</span><span style="width:7.9pt; text-indent:0pt; font-size:11pt; display:inline-block"> </span><span style="font-size:11pt">Newcastle;</span></p><p class="P3" style="margin-top:0pt; margin-left:72.6pt; text-indent:-72.6pt"><span style="width:45.38pt; text-indent:0pt; font-size:11pt; display:inline-block"></span><span style="font-size:11pt">(O)</span><span style="width:7.9pt; text-indent:0pt; font-size:11pt; display:inline-block"> </span><span style="font-size:11pt">North Canberra;</span></p><p class="P3" style="margin-top:0pt; margin-left:72.6pt; text-indent:-72.6pt"><span style="width:47.21pt; text-indent:0pt; font-size:11pt; display:inline-block"></span><span style="font-size:11pt">(P)</span><span style="width:7.9pt; text-indent:0pt; font-size:11pt; display:inline-block"> </span><span style="font-size:11pt">Palmerston</span><span style="font-size:11pt">‑</span><span style="font-size:11pt">East Arm;</span></p><p class="P3" style="margin-top:0pt; margin-left:72.6pt; text-indent:-72.6pt"><span style="width:45.38pt; text-indent:0pt; font-size:11pt; display:inline-block"></span><span style="font-size:11pt">(Q)</span><span style="width:7.9pt; text-indent:0pt; font-size:11pt; display:inline-block"> </span><span style="font-size:11pt">Pine Rivers Shire;</span></p><p class="P3" style="margin-top:0pt; margin-left:72.6pt; text-indent:-72.6pt"><span style="width:45.99pt; text-indent:0pt; font-size:11pt; display:inline-block"></span><span style="font-size:11pt">(R)</span><span style="width:7.9pt; text-indent:0pt; font-size:11pt; display:inline-block"> </span><span style="font-size:11pt">Queanbeyan;</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span></span></p></td></tr><tr style="height:97.5pt"><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span></span></p></td><td style="width:285.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="P3" style="margin-top:0pt; margin-left:72.6pt; text-indent:-72.6pt"><span style="width:47.21pt; text-indent:0pt; font-size:11pt; display:inline-block"></span><span style="font-size:11pt">(S)</span><span style="width:7.9pt; text-indent:0pt; font-size:11pt; display:inline-block"> </span><span style="font-size:11pt">South Canberra;</span></p><p class="P3" style="margin-top:0pt; margin-left:72.6pt; text-indent:-72.6pt"><span style="width:46.6pt; text-indent:0pt; font-size:11pt; display:inline-block"></span><span style="font-size:11pt">(T)</span><span style="width:7.9pt; text-indent:0pt; font-size:11pt; display:inline-block"> </span><span style="font-size:11pt">South Eastern Outer Melbourne;</span></p><p class="P3" style="margin-top:0pt; margin-left:72.6pt; text-indent:-72.6pt"><span style="width:45.38pt; text-indent:0pt; font-size:11pt; display:inline-block"></span><span style="font-size:11pt">(U)</span><span style="width:7.9pt; text-indent:0pt; font-size:11pt; display:inline-block"> </span><span style="font-size:11pt">Southern Adelaide;</span></p><p class="P3" style="margin-top:0pt; margin-left:72.6pt; text-indent:-72.6pt"><span style="width:45.38pt; text-indent:0pt; font-size:11pt; display:inline-block"></span><span style="font-size:11pt">(V)</span><span style="width:7.9pt; text-indent:0pt; font-size:11pt; display:inline-block"> </span><span style="font-size:11pt">South West Metropolitan;</span></p><p class="P3" style="margin-top:0pt; margin-left:72.6pt; text-indent:-72.6pt"><span style="width:42.94pt; text-indent:0pt; font-size:11pt; display:inline-block"></span><span style="font-size:11pt">(W)</span><span style="width:7.9pt; text-indent:0pt; font-size:11pt; display:inline-block"> </span><span style="font-size:11pt">Thuringowa City Part A;</span></p><p class="P3" style="margin-top:0pt; margin-left:72.6pt; text-indent:-72.6pt"><span style="width:45.38pt; text-indent:0pt; font-size:11pt; display:inline-block"></span><span style="font-size:11pt">(X)</span><span style="width:7.9pt; text-indent:0pt; font-size:11pt; display:inline-block"> </span><span style="font-size:11pt">Townsville City Part A;</span></p><p class="P3" style="margin-top:0pt; margin-left:72.6pt; text-indent:-72.6pt"><span style="width:45.38pt; text-indent:0pt; font-size:11pt; display:inline-block"></span><span style="font-size:11pt">(Y)</span><span style="width:7.9pt; text-indent:0pt; font-size:11pt; display:inline-block"> </span><span style="font-size:11pt">Tuggeranong;</span></p><p class="P3" style="margin-top:0pt; margin-left:72.6pt; text-indent:-72.6pt"><span style="width:46.6pt; text-indent:0pt; font-size:11pt; display:inline-block"></span><span style="font-size:11pt">(Z)</span><span style="width:7.9pt; text-indent:0pt; font-size:11pt; display:inline-block"> </span><span style="font-size:11pt">Weston Creek</span><span style="font-size:11pt">‑</span><span style="font-size:11pt">Stromlo;</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span></span></p></td></tr><tr style="height:53.85pt"><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span></span></p></td><td style="width:285.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="P3" style="margin-top:0pt; margin-left:72.6pt; text-indent:-72.6pt"><span style="width:38.66pt; text-indent:0pt; font-size:11pt; display:inline-block"></span><span style="font-size:11pt">(ZA)</span><span style="width:7.9pt; text-indent:0pt; font-size:11pt; display:inline-block"> </span><span style="font-size:11pt">Woden Valley;</span></p><p class="P3" style="margin-top:0pt; margin-left:72.6pt; text-indent:-72.6pt; page-break-before:always; page-break-inside:avoid; page-break-after:avoid"><span style="width:39.27pt; text-indent:0pt; font-size:11pt; display:inline-block"></span><span style="font-size:11pt">(ZB)</span><span style="width:7.9pt; text-indent:0pt; font-size:11pt; display:inline-block"> </span><span style="font-size:11pt">Yarra Ranges Shire Part A; or</span></p><p class="P3" style="margin-top:0pt; margin-left:72.6pt; text-indent:-72.6pt"><span style="width:43.32pt; text-indent:0pt; display:inline-block"></span><span>(iv)</span><span style="width:7.9pt; text-indent:0pt; display:inline-block"> </span><span>the geographical area included in the SLA spatial unit of Palm Island (AC)</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span></span></p></td></tr><tr style="height:19.85pt"><td colspan="7" style="width:377.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableColHead"><span>Group P13</span><span> </span><span>—</span><span> </span><span>Bulk billing incentive for episodes consisting of a P10 service</span></p></td></tr><tr style="height:19.85pt"><td colspan="7" style="width:377.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="Note" style="margin-left:0pt"><span style="font-style:italic">Note</span><span> </span><span></span><span></span><span>The payments mentioned in column 3 of Group</span><span> </span><span>P13 are additional payments for bulk billing a patient episode consisting of a pathology service to which a Group P10 item described in column</span><span> </span><span>2 applies.</span></p></td></tr><tr style="height:52.35pt"><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>74992</span></p></td><td style="width:285.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A patient episode that:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>consists of a pathology service to which item 73920 applies; and</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>is bulk billed</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>1.60</span></p></td></tr><tr style="height:52.35pt"><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>74993</span></p></td><td style="width:285.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A patient episode that:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>consists of a pathology service to which item 73922 or 73926 applies; and</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>is bulk billed</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>3.75</span></p></td></tr><tr style="height:52.35pt"><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>74994</span></p></td><td style="width:285.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A patient episode that:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>consists of a pathology service to which item 73924 applies; and</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b) </span><span style="width:3.5pt; text-indent:0pt; display:inline-block"></span><span>is bulk billed</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>3.25</span></p></td></tr><tr style="height:52.35pt"><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>74995</span></p></td><td style="width:285.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A patient episode that:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a) </span><span style="width:3.5pt; text-indent:0pt; display:inline-block"></span><span>consists of a pathology service to which item 73928, 73930 or 73936 applies; and</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>is bulk billed</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>4.00</span></p></td></tr><tr style="height:28.35pt"><td colspan="2" style="width:36.2pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText"><span>74996</span></p></td><td style="width:285.4pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText"><span>A patient episode that:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>consists of a pathology service to which item 73932 or 73940 applies; and</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>is bulk billed</span></p></td><td colspan="4" style="width:34.15pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText"><span>3.70</span></p></td></tr><tr style="height:52.35pt"><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>74997</span></p></td><td style="width:285.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A patient episode that:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>consists of a pathology service item 73934 applies; and</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>is bulk billed</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>3.30</span></p></td></tr><tr style="height:52.35pt"><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>74998</span></p></td><td style="width:285.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A patient episode that:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>consists of a pathology service to which to which item 73938 applies; and</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>is bulk billed</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>2.00</span></p></td></tr><tr style="height:52.35pt"><td colspan="2" style="width:36.3pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>74999</span></p></td><td style="width:285.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A patient episode that:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>consists of a pathology service to which item 73923, 73925, 73927, 73929, 73931, 73933, 73935, 73937 or 73939 applies; and</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>is bulk billed</span></p></td><td colspan="4" style="width:34.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>1.60</span></p></td></tr><tr style="height:0pt"><td style="width:42.95pt"></td><td style="width:4.05pt"></td><td style="width:296.2pt"></td><td style="width:1pt"></td><td style="width:0.9pt"></td><td style="width:0.95pt"></td><td style="width:42.1pt"></td></tr></tbody></table>